Skip to main content

Myles Selig Wolf

Charles Johnson, M.D. Distinguished Professor of Medicine
Medicine, Nephrology

Selected Publications


Intravenous iron-induced hypophosphatemia and kidney stone disease

Journal Article Bone Reports · June 1, 2024 Patients with Crohn's disease are at increased risk for symptomatic nephrolithiasis. Stones in these patients are most commonly composed of calcium oxalate monohydrate or mixed calcium-oxalate and calcium-phosphate. Precipitation of both minerals depends o ... Full text Cite

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Journal Article Nat Med · May 25, 2024 Inflammation mediated by interleukin-6 (IL-6) is strongly associated with cardiovascular risk. Here we evaluated clazakizumab, a monoclonal antibody targeting the IL-6 ligand, in a phase 2b dose-finding study. Adults with cardiovascular disease and/or diab ... Full text Link to item Cite

Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study.

Journal Article J Bone Miner Res · May 2, 2024 Fracture risk is high in chronic kidney disease (CKD) and underlying pathophysiology and risk factors may differ from the general population. In a cohort study of 3939 participants in the chronic renal insufficiency cohort (CRIC), we used Cox regression to ... Full text Link to item Cite

Associations of Kidney Functional Magnetic Resonance Imaging Biomarkers with Markers of Inflammation in Individuals with CKD.

Journal Article Kidney360 · May 1, 2024 KEY POINTS: Lower baseline apparent diffusion coefficient, indicative of greater cortical fibrosis, correlated with higher baseline concentrations of serum markers of inflammation. No association between baseline cortical R2* and baseline serum markers of ... Full text Link to item Cite

Klotho and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.

Journal Article Am J Kidney Dis · April 6, 2024 RATIONALE & OBJECTIVE: Klotho deficiency may affect clinical outcomes in chronic kidney disease (CKD) through fibroblast growth factor-23 (FGF23)-dependent and -independent pathways. However, the association between circulating Klotho and clinical outcomes ... Full text Link to item Cite

Targeting Gut Microbiome With Prebiotic in Patients With CKD: The TarGut-CKD Study.

Journal Article Kidney Int Rep · March 2024 INTRODUCTION: Disruption of gut microbiota underpins some of the metabolic alterations observed in chronic kidney disease (CKD). METHODS: In a nonrandomized, open-label, 3-phase pilot trial, with repeated measures within each phase, we examined the efficac ... Full text Link to item Cite

Calcium and Phosphate Disorders: Core Curriculum 2024.

Journal Article Am J Kidney Dis · February 2024 Maintaining normal calcium and phosphate homeostasis is essential for optimal cellular, metabolic, and organ function. Parathyroid hormone, fibroblast growth factor 23, and 1,25-dihydroxyvitamin D regulate calcium and phosphate homeostasis via multiple int ... Full text Link to item Cite

FGF23 and klotho at the intersection of kidney and cardiovascular disease.

Journal Article Nat Rev Cardiol · January 2024 Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD). As CKD progresses, CKD-specific risk factors, such as disordered mineral homeostasis, amplify traditional cardiovascular risk factors. Fibroblast growth fac ... Full text Link to item Cite

Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial.

Journal Article J Am Soc Nephrol · January 1, 2024 SIGNIFICANCE STATEMENT: In CKD, metabolic acidosis is commonly treated with alkali in the hope that it will improve bone health. In a post hoc analysis of the Bicarbonate Administration to Stabilize eGFR Pilot Trial, we investigated whether sodium bicarbon ... Full text Link to item Cite

Incidence, mechanism, and consequences of IV iron-induced hypophosphatemia.

Journal Article Hematology Am Soc Hematol Educ Program · December 8, 2023 Full text Link to item Cite

Fibroblast Growth Factor 23 and Risk of Heart Failure Subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Journal Article Kidney Med · November 2023 RATIONALE & OBJECTIVE: Heart failure (HF) is an important cause of morbidity and mortality among individuals with chronic kidney disease (CKD). A large body of evidence from preclinical and clinical studies implicates excess levels of fibroblast growth fac ... Full text Link to item Cite

Plasma Serotonin and Cardiovascular Outcomes in Chronic Kidney Disease.

Journal Article J Am Heart Assoc · September 5, 2023 Background Platelet-poor plasma serotonin levels are associated with adverse cardiovascular outcomes. Although plasma serotonin levels increase in chronic kidney disease, the cardiovascular implications remain unknown. Methods and Results In 1114 participa ... Full text Link to item Cite

Associations of FGF23 with 10-Year Change in eGFR and UACR and with Incident CKD in the CARDIA Cohort.

Journal Article Kidney360 · September 1, 2023 KEY POINTS: FGF23 has a nonlinear positive association with incident CKD among healthy, middle-aged adults. The relationship between FGF23 and incident CKD was only significant among participants with cFGF23 levels in the highest quartile. FGF23 is not ass ... Full text Link to item Cite

Exploring US internal medicine resident career preferences: a Q-methodology study.

Journal Article Adv Health Sci Educ Theory Pract · August 2023 Career selection in medicine is a complex and underexplored process. Most medical career studies performed in the U.S. focused on the effect of demographic variables and medical education debt on career choice. Considering ongoing U.S. physician workforce ... Full text Link to item Cite

Vitamin D Metabolites and Risk of Cardiovascular Disease in Chronic Kidney Disease: The CRIC Study.

Journal Article J Am Heart Assoc · July 18, 2023 Background The ratio of 24,25-dihydroxyvitamin D3/25-hydroxyvitamin D3 (vitamin D metabolite ratio [VDMR]) may reflect functional vitamin D activity. We examined associations of the VDMR, 25-hydroxyvitamin D (25[OH]D), and 1,25-dihydroxyvitamin D (1,25[OH] ... Full text Link to item Cite

Matryoshka hormones.

Journal Article Blood · July 6, 2023 Full text Link to item Cite

Sildenafil and Kidney Function in Heart Failure with Preserved Ejection Fraction.

Journal Article Kidney360 · May 1, 2023 KEY POINTS: Sildenafil induced an acute effect on eGFR without change in the overall eGFR slope after 24 weeks in a heart failure with preserved ejection fraction (HFpEF) cohort. N-terminal pro–brain natriuretic peptide levels and baseline diuretic use wer ... Full text Link to item Cite

Renal proximal tubule cells: power and finesse.

Journal Article The Journal of clinical investigation · May 2023 The proximal tubule is the high-capacity reabsorptive powerhouse of the kidney. Two papers in recent issues of the JCI highlight mechanisms of more delicate effects of the proximal tubule. Yoon et al. demonstrated the intracellular mechanism by which parat ... Full text Cite

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.

Journal Article Gut · April 2023 OBJECTIVE: Intravenous iron-a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD)-can cause hypophosphataemia. This trial compared the incidence of hypophosphataemia after treatment with ferric carboxymaltose (FCM) or f ... Full text Link to item Cite

Intravenous iron-induced hypophosphatemia and kidney stone disease

Journal Article Bone Reports · June 1, 2024 Patients with Crohn's disease are at increased risk for symptomatic nephrolithiasis. Stones in these patients are most commonly composed of calcium oxalate monohydrate or mixed calcium-oxalate and calcium-phosphate. Precipitation of both minerals depends o ... Full text Cite

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Journal Article Nat Med · May 25, 2024 Inflammation mediated by interleukin-6 (IL-6) is strongly associated with cardiovascular risk. Here we evaluated clazakizumab, a monoclonal antibody targeting the IL-6 ligand, in a phase 2b dose-finding study. Adults with cardiovascular disease and/or diab ... Full text Link to item Cite

Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study.

Journal Article J Bone Miner Res · May 2, 2024 Fracture risk is high in chronic kidney disease (CKD) and underlying pathophysiology and risk factors may differ from the general population. In a cohort study of 3939 participants in the chronic renal insufficiency cohort (CRIC), we used Cox regression to ... Full text Link to item Cite

Associations of Kidney Functional Magnetic Resonance Imaging Biomarkers with Markers of Inflammation in Individuals with CKD.

Journal Article Kidney360 · May 1, 2024 KEY POINTS: Lower baseline apparent diffusion coefficient, indicative of greater cortical fibrosis, correlated with higher baseline concentrations of serum markers of inflammation. No association between baseline cortical R2* and baseline serum markers of ... Full text Link to item Cite

Klotho and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.

Journal Article Am J Kidney Dis · April 6, 2024 RATIONALE & OBJECTIVE: Klotho deficiency may affect clinical outcomes in chronic kidney disease (CKD) through fibroblast growth factor-23 (FGF23)-dependent and -independent pathways. However, the association between circulating Klotho and clinical outcomes ... Full text Link to item Cite

Targeting Gut Microbiome With Prebiotic in Patients With CKD: The TarGut-CKD Study.

Journal Article Kidney Int Rep · March 2024 INTRODUCTION: Disruption of gut microbiota underpins some of the metabolic alterations observed in chronic kidney disease (CKD). METHODS: In a nonrandomized, open-label, 3-phase pilot trial, with repeated measures within each phase, we examined the efficac ... Full text Link to item Cite

Calcium and Phosphate Disorders: Core Curriculum 2024.

Journal Article Am J Kidney Dis · February 2024 Maintaining normal calcium and phosphate homeostasis is essential for optimal cellular, metabolic, and organ function. Parathyroid hormone, fibroblast growth factor 23, and 1,25-dihydroxyvitamin D regulate calcium and phosphate homeostasis via multiple int ... Full text Link to item Cite

FGF23 and klotho at the intersection of kidney and cardiovascular disease.

Journal Article Nat Rev Cardiol · January 2024 Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD). As CKD progresses, CKD-specific risk factors, such as disordered mineral homeostasis, amplify traditional cardiovascular risk factors. Fibroblast growth fac ... Full text Link to item Cite

Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial.

Journal Article J Am Soc Nephrol · January 1, 2024 SIGNIFICANCE STATEMENT: In CKD, metabolic acidosis is commonly treated with alkali in the hope that it will improve bone health. In a post hoc analysis of the Bicarbonate Administration to Stabilize eGFR Pilot Trial, we investigated whether sodium bicarbon ... Full text Link to item Cite

Incidence, mechanism, and consequences of IV iron-induced hypophosphatemia.

Journal Article Hematology Am Soc Hematol Educ Program · December 8, 2023 Full text Link to item Cite

Fibroblast Growth Factor 23 and Risk of Heart Failure Subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Journal Article Kidney Med · November 2023 RATIONALE & OBJECTIVE: Heart failure (HF) is an important cause of morbidity and mortality among individuals with chronic kidney disease (CKD). A large body of evidence from preclinical and clinical studies implicates excess levels of fibroblast growth fac ... Full text Link to item Cite

Plasma Serotonin and Cardiovascular Outcomes in Chronic Kidney Disease.

Journal Article J Am Heart Assoc · September 5, 2023 Background Platelet-poor plasma serotonin levels are associated with adverse cardiovascular outcomes. Although plasma serotonin levels increase in chronic kidney disease, the cardiovascular implications remain unknown. Methods and Results In 1114 participa ... Full text Link to item Cite

Associations of FGF23 with 10-Year Change in eGFR and UACR and with Incident CKD in the CARDIA Cohort.

Journal Article Kidney360 · September 1, 2023 KEY POINTS: FGF23 has a nonlinear positive association with incident CKD among healthy, middle-aged adults. The relationship between FGF23 and incident CKD was only significant among participants with cFGF23 levels in the highest quartile. FGF23 is not ass ... Full text Link to item Cite

Exploring US internal medicine resident career preferences: a Q-methodology study.

Journal Article Adv Health Sci Educ Theory Pract · August 2023 Career selection in medicine is a complex and underexplored process. Most medical career studies performed in the U.S. focused on the effect of demographic variables and medical education debt on career choice. Considering ongoing U.S. physician workforce ... Full text Link to item Cite

Vitamin D Metabolites and Risk of Cardiovascular Disease in Chronic Kidney Disease: The CRIC Study.

Journal Article J Am Heart Assoc · July 18, 2023 Background The ratio of 24,25-dihydroxyvitamin D3/25-hydroxyvitamin D3 (vitamin D metabolite ratio [VDMR]) may reflect functional vitamin D activity. We examined associations of the VDMR, 25-hydroxyvitamin D (25[OH]D), and 1,25-dihydroxyvitamin D (1,25[OH] ... Full text Link to item Cite

Matryoshka hormones.

Journal Article Blood · July 6, 2023 Full text Link to item Cite

Sildenafil and Kidney Function in Heart Failure with Preserved Ejection Fraction.

Journal Article Kidney360 · May 1, 2023 KEY POINTS: Sildenafil induced an acute effect on eGFR without change in the overall eGFR slope after 24 weeks in a heart failure with preserved ejection fraction (HFpEF) cohort. N-terminal pro–brain natriuretic peptide levels and baseline diuretic use wer ... Full text Link to item Cite

Renal proximal tubule cells: power and finesse.

Journal Article The Journal of clinical investigation · May 2023 The proximal tubule is the high-capacity reabsorptive powerhouse of the kidney. Two papers in recent issues of the JCI highlight mechanisms of more delicate effects of the proximal tubule. Yoon et al. demonstrated the intracellular mechanism by which parat ... Full text Cite

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.

Journal Article Gut · April 2023 OBJECTIVE: Intravenous iron-a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD)-can cause hypophosphataemia. This trial compared the incidence of hypophosphataemia after treatment with ferric carboxymaltose (FCM) or f ... Full text Link to item Cite

Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.

Journal Article J Hepatol · March 2023 BACKGROUND & AIMS: The LIVIFY trial investigated the safety, tolerability, and efficacy of vonafexor, a second-generation, non-bile acid farnesoid X receptor agonist in patients with suspected fibrotic non-alcoholic steatohepatitis (NASH). METHODS: This do ... Full text Link to item Cite

Supermarket Proximity and Risk of Hypertension, Diabetes, and CKD: A Retrospective Cohort Study.

Journal Article Am J Kidney Dis · February 2023 RATIONALE & OBJECTIVE: Living in environments with low access to food may increase the risk of chronic diseases. We investigated the association of household distance to the nearest supermarket (as a measure of food access) with the incidence of hypertensi ... Full text Link to item Cite

Magnesium and Fracture Risk in the General Population and Patients Receiving Dialysis: A Narrative Review.

Journal Article Can J Kidney Health Dis · 2023 PURPOSE OF REVIEW: Magnesium is an essential mineral for bone metabolism, but little is known about how magnesium intake alters fracture risk. We conducted a narrative review to better understand how magnesium intake, through supplementation, diet, or alte ... Full text Link to item Cite

Exercising the FGF23-Cardiac Axis.

Journal Article Kidney360 · September 29, 2022 Full text Link to item Cite

The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Secondary and Tertiary Renal Hyperparathyroidism.

Journal Article Ann Surg · September 1, 2022 OBJECTIVE: To develop evidence-based recommendations for safe, effective, and appropriate treatment of secondary (SHPT) and tertiary (THPT) renal hyperparathyroidism. BACKGROUND: Hyperparathyroidism is common among patients with chronic kidney disease, end ... Full text Link to item Cite

Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.

Journal Article J Clin Endocrinol Metab · March 24, 2022 CONTEXT: Hypophosphatemia, osteomalacia, and fractures are complications of certain intravenous iron formulations. OBJECTIVE: This study investigated risk factors for incident, severe, and persistent hypophosphatemia, and associated alterations in bone and ... Full text Link to item Cite

Fibroblast growth factor-23 and subclinical markers of cardiac dysfunction: The coronary artery risk development in young adults (CARDIA) study.

Journal Article Am Heart J · March 2022 BACKGROUND: Elevated Fibroblast Growth Factor-23 (FGF23) levels have been associated with greater left ventricular mass (LVM) and heart failure. Whether higher FGF23 is associated with higher LVH prevalence and longitudinal changes in LVM and myocardial st ... Full text Link to item Cite

Risk Prediction Models for Atherosclerotic Cardiovascular Disease in Patients with Chronic Kidney Disease: The CRIC Study.

Journal Article J Am Soc Nephrol · March 2022 BACKGROUND: Individuals with CKD may be at high risk for atherosclerotic cardiovascular disease (ASCVD). However, there are no ASCVD risk prediction models developed in CKD populations to inform clinical care and prevention. METHODS: We developed and valid ... Full text Link to item Cite

Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial.

Journal Article Kidney360 · February 24, 2022 BACKGROUND: Individuals with CKD have a high burden of cardiovascular disease (CVD). Abnormalities in cardiac structure and function represent subclinical CVD and can be assessed by cardiac magnetic resonance imaging (cMRI). METHODS: We investigated differ ... Full text Link to item Cite

Time-Updated Changes in Estimated GFR and Proteinuria and Major Adverse Cardiac Events: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.

Journal Article Am J Kidney Dis · January 2022 RATIONALE & OBJECTIVE: Evaluating repeated measures of estimated glomerular filtration rate (eGFR) and urinary protein-creatinine ratio (UPCR) over time may enhance our ability to understand the association between changes in kidney parameters and cardiova ... Full text Link to item Cite

A Comparative Study of Serum Phosphate and Related Parameters in Chronic Kidney Disease between the USA and Japan.

Journal Article Am J Nephrol · 2022 INTRODUCTION: Recent studies have suggested a higher incidence of cardiovascular disease (CVD) among patients with chronic kidney disease (CKD) in the USA than in Japan. Hyperphosphatemia, a possible risk for CVD, may explain this difference; however, inte ... Full text Link to item Cite

Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management.

Journal Article Bone · January 2022 Contemporary intravenous iron formulations allow administration of high doses of elemental iron and enable correction of total iron deficit in one or two infusions. An important but underappreciated complication of certain formulations is hypophosphatemia ... Full text Link to item Cite

Association of circulating cardiac biomarkers with electrocardiographic abnormalities in chronic kidney disease.

Journal Article Nephrol Dial Transplant · December 2, 2021 BACKGROUND: Among patients with chronic kidney disease (CKD), the circulating cardiac biomarkers soluble ST2 (SST2), galectin-3, growth differentiation factor-15 (GDF-15), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin- ... Full text Link to item Cite

Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease.

Journal Article Kidney Int · December 2021 Disordered iron and mineral homeostasis are interrelated complications of chronic kidney disease that may influence cardiovascular and kidney outcomes. In a prospective analysis of 3747 participants in the Chronic Renal Insufficiency Cohort Study, we inves ... Full text Link to item Cite

Noninvasive Risk Score to Screen for Pulmonary Hypertension With Elevated Pulmonary Vascular Resistance in Diseases of Chronic Volume Overload.

Journal Article Am J Cardiol · November 15, 2021 Volume overload promotes pulmonary hypertension (PH) through pulmonary venous hypertension. However, PH with elevated pulmonary vascular resistance (hereafter PH-PVR) may develop in patients with diseases of volume overload, such as heart failure or chroni ... Full text Link to item Cite

Race, Genetic Ancestry, and Estimating Kidney Function in CKD.

Journal Article N Engl J Med · November 4, 2021 BACKGROUND: The inclusion of race in equations to estimate the glomerular filtration rate (GFR) has become controversial. Alternative equations that can be used to achieve similar accuracy without the use of race are needed. METHODS: In a large national st ... Full text Link to item Cite

Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle-Aged Adults.

Journal Article J Am Heart Assoc · August 17, 2021 Background Higher circulating fibroblast growth factor 23 (FGF23) associates with greater risk of cardiovascular disease (CVD) and mortality in older adults. The association of FGF23 with cardiovascular outcomes in younger populations has been incompletely ... Full text Link to item Cite

Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease.

Journal Article Bone Res · August 2, 2021 Bone-produced fibroblast growth factor 23 (FGF23) increases in response to inflammation and iron deficiency and contributes to cardiovascular mortality in chronic kidney disease (CKD). Neutrophil gelatinase-associated lipocalin (NGAL or lipocalin 2; LCN2 t ... Full text Link to item Cite

Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.

Journal Article Adv Ther · July 2021 Some, but not all, intravenous iron formulations have been recognized to induce renal phosphate wasting syndrome. Most commonly this has been reported following treatment of iron deficiency anemia (IDA) with ferric carboxymaltose (FCM). A search of PubMed ... Full text Link to item Cite

Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis.

Journal Article Am J Kidney Dis · June 2021 RATIONALE & OBJECTIVE: Hyperphosphatemia is a risk factor for poor clinical outcomes in patients with kidney failure receiving maintenance dialysis. Opinion-based clinical practice guidelines recommend the use of phosphate binders and dietary phosphate res ... Full text Link to item Cite

Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Journal Article Am J Kidney Dis · June 2021 RATIONALE & OBJECTIVE: Circulating cardiac biomarkers may signal potential mechanistic pathways involved in heart failure (HF) and atrial fibrillation (AF). Single measures of circulating cardiac biomarkers are strongly associated with incident HF and AF i ... Full text Link to item Cite

Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.

Conference Kidney Int · June 2021 In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluati ... Full text Link to item Cite

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.

Journal Article Br J Clin Pharmacol · May 2021 AIMS: Hypophosphataemia is an increasingly recognized side-effect of ferric carboxymaltose (FCM) and possibly iron isomaltoside/ferric derisomaltose (IIM), which are used to treat iron deficiency. The aim of this study was to determine frequency, severity, ... Full text Link to item Cite

International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in North America and the Caribbean

Journal Article Kidney International Supplements · May 1, 2021 The International Society of Nephrology established the Global Kidney Health Atlas project to define the global capacity for kidney replacement therapy and conservative kidney care, and this second iteration was to describe the availability, accessibility, ... Full text Cite

Mineral bone disease in autosomal dominant polycystic kidney disease.

Journal Article Kidney Int · April 2021 Mice with disruption of Pkd1 in osteoblasts demonstrate reduced bone mineral density, trabecular bone volume and cortical thickness. To date, the bone phenotype in adult patients with autosomal dominant polycystic kidney disease (ADPKD) with stage I and II ... Full text Link to item Cite

Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction.

Journal Article Journal of cardiac failure · March 2021 BackgroundHeart failure with preserved ejection fraction (HFpEF) is characterized by left ventricular hypertrophy and decreased exercise capacity. Fibroblast growth factor 23 (FGF23), a hormone involved in phosphate, vitamin D, and iron homeostasi ... Full text Cite

Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.

Journal Article Am J Kidney Dis · January 2021 RATIONALE & OBJECTIVE: Identification of novel risk factors for chronic kidney disease (CKD) progression may inform mechanistic investigations and improve identification of high-risk subgroups. The current study aimed to characterize CKD progression across ... Full text Link to item Cite

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.

Journal Article Nephrol Dial Transplant · January 1, 2021 BACKGROUND: The optimal intravenous (IV) iron would allow safe correction of iron deficiency at a single infusion over a short time. The FERWON-NEPHRO trial evaluated the safety and efficacy of iron isomaltoside 1000/ferric derisomaltose (IIM) in patients ... Full text Link to item Cite

Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.

Journal Article Bone · December 2020 BACKGROUND: Two weekly infusions of ferric carboxymaltose (FCM) are commonly prescribed for treatment of iron-deficiency anemia. However, administration of FCM increases intact levels of fibroblast growth factor 23 (FGF23), which causes hypophosphatemia du ... Full text Link to item Cite

Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference.

Journal Article Am J Kidney Dis · December 2020 Occasional bursts of discovery and innovation have appeared during the otherwise stagnant past several decades of drug development in nephrology. Among other recent drug discoveries, the unexpected kidney benefits observed with sodium/glucose cotransporter ... Full text Link to item Cite

Echocardiography to Screen for Pulmonary Hypertension in CKD.

Journal Article Kidney Int Rep · December 2020 INTRODUCTION: Pulmonary hypertension (PH) is a common yet incompletely understood complication of chronic kidney disease (CKD). Although transthoracic echocardiogram is commonly used to noninvasively estimate PH, it has not been validated in a CKD populati ... Full text Open Access Link to item Cite

Racial Differences in the Associations Between Food Insecurity and Fibroblast Growth Factor 23 in the Coronary Artery Risk Development in Young Adults Study.

Journal Article J Ren Nutr · November 2020 OBJECTIVE: Food insecurity is associated with consumption of phosphate additive-laden processed food and beverage products, which could result in higher levels of fibroblast growth factor 23 (FGF23) to compensate for the increased dietary phosphate load. W ... Full text Link to item Cite

Fibroblast Growth Factor-23 and a Vegetarian Diet.

Journal Article J Ren Nutr · November 2020 OBJECTIVE: Sparse data exist on population distributions of serum fibroblast growth factor-23 (FGF23) levels from developing, middle-income economies. FGF23 levels may differ substantially across regions based on differences in diet and urbanization. In a ... Full text Link to item Cite

Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting.

Journal Article Ther Innov Regul Sci · November 2020 In late 2018, the Food and Drug Administration (FDA) outlined a framework for evaluating the possible use of real-world evidence (RWE) to support regulatory decision-making. This framework was created to facilitate studies that would generate high-quality ... Full text Link to item Cite

Association between patient race and staff resuscitation efforts after cardiac arrest in outpatient dialysis clinics: A study from the CARES surveillance group.

Journal Article Resuscitation · November 2020 BACKGROUND: Cardiac arrest is the leading cause of death among patients receiving hemodialysis. Despite guidelines recommending CPR training and AED presence in dialysis clinics, rates of CPR and AED use by dialysis staff are suboptimal. Given that racial ... Full text Open Access Link to item Cite

The Nephrology Immersion Classroom for Internal Medicine Residents.

Journal Article Kidney360 · October 29, 2020 BACKGROUND: In graduate medical education (GME), there are many barriers to achieving a personalized learning process with standardized learning outcomes. One way to support this is through mobile-friendly digital blackboard videos. We sought to measure th ... Full text Link to item Cite

Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.

Journal Article Br J Pharmacol · October 2020 BACKGROUND AND PURPOSE: No therapy is approved for vascular calcification or calcific uraemic arteriolopathy (calciphylaxis), which increases mortality and morbidity in patients undergoing dialysis. Deposition of hydroxyapatite (HAP) crystals in arterial w ... Full text Link to item Cite

Nephropathic Cystinosis: A Distinct Form of CKD-Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23.

Journal Article J Am Soc Nephrol · September 2020 BACKGROUND: The rare lysosomal storage disease nephropathic cystinosis presents with renal Fanconi syndrome that evolves in time to CKD. Although biochemical abnormalities in common causes of CKD-mineral and bone disorder have been defined, it is unknown i ... Full text Link to item Cite

Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Journal Article J Am Soc Nephrol · August 2020 BACKGROUND: Risk of infectious disease is increased among individuals with CKD. Fibroblast growth factor 23 (FGF23) is often elevated in CKD, and may impair immune function directly or indirectly through proinflammatory and vitamin D-suppressing pathways. ... Full text Link to item Cite

Anemia and Incident End-Stage Kidney Disease.

Journal Article Kidney360 · July 30, 2020 BACKGROUND: Chronic kidney disease (CKD) progression can be a cause and potentially a consequence of anemia. Previous studies suggesting that anemia is associated with CKD progression have not utilized methodologic approaches to address time-dependent conf ... Full text Link to item Cite

Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease.

Journal Article Kidney360 · July 2020 BACKGROUND: Higher serum intact fibroblast growth factor 23 (iFGF23) was associated with disease progression in participants with autosomal dominant polycystic kidney disease (ADPKD) in the HALT-PKD Studies. PKD mutation is also an important determinant of ... Full text Link to item Cite

Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD.

Journal Article Clin J Am Soc Nephrol · June 8, 2020 BACKGROUND AND OBJECTIVES: Kidney functional magnetic resonance imaging (MRI) requires further investigation to enhance the noninvasive identification of patients at high risk of CKD progression. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this explo ... Full text Link to item Cite

Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Journal Article Am J Kidney Dis · June 2020 RATIONALE & OBJECTIVE: Studies using a single measurement of fibroblast growth factor 23 (FGF-23) suggest that elevated FGF-23 levels are associated with increased risk for requirement for kidney replacement therapy (KRT) in patients with chronic kidney di ... Full text Link to item Cite

Inflammatory Markers and Incidence of Hospitalization With Infection in Chronic Kidney Disease.

Journal Article Am J Epidemiol · May 5, 2020 Persons with chronic kidney disease (CKD) are at high risk of infection. While low-grade inflammation could impair immune response, it is unknown whether inflammatory markers are associated with infection risk in this clinical population. Using 2003-2013 d ... Full text Link to item Cite

Pulmonary Hypertension Subtypes and Mortality in CKD.

Journal Article Am J Kidney Dis · May 2020 RATIONALE & OBJECTIVE: Pulmonary hypertension (PH) contributes to cardiovascular disease and mortality in patients with chronic kidney disease (CKD), but the pathophysiology is mostly unknown. This study sought to estimate the prevalence and consequences o ... Full text Open Access Link to item Cite

Targeting Vascular Calcification in Chronic Kidney Disease.

Journal Article JACC Basic Transl Sci · April 2020 Cardiovascular (CV) disease remains an important cause of morbidity and mortality for patients with chronic kidney disease (CKD). Although clustering of traditional risk factors with CKD is well recognized, kidney-specific mechanisms are believed to drive ... Full text Link to item Cite

Kidney to bone via bedside to bench…and back?

Journal Article J Clin Invest · March 2, 2020 The rapid rise in circulating fibroblast growth factor 23 (FGF23) associated with kidney injury results in calcitriol deficiency, altered calcium homeostasis, and secondary hyperparathyroidism, and may contribute to cardiovascular complications and death. ... Full text Link to item Cite

Regulation and Effects of FGF23 in Chronic Kidney Disease.

Book · February 10, 2020 Chronic kidney disease (CKD) is a global health epidemic that accelerates cardiovascular disease, increases risk of infection, and causes anemia and bone disease, among other complications that collectively increase risk of premature death. Alterations in ... Full text Link to item Cite

Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.

Journal Article JAMA · February 4, 2020 IMPORTANCE: Intravenous iron enables rapid correction of iron-deficiency anemia, but certain formulations induce fibroblast growth factor 23-mediated hypophosphatemia. OBJECTIVE: To compare risks of hypophosphatemia and effects on biomarkers of mineral and ... Full text Link to item Cite

Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Journal Article Am J Kidney Dis · February 2020 RATIONALE & OBJECTIVE: The pathogenesis of disordered mineral metabolism in chronic kidney disease (CKD) is largely informed by cross-sectional studies of humans and longitudinal animal studies. We sought to characterize the longitudinal evolution of disor ... Full text Link to item Cite

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis.

Journal Article Clin Kidney J · February 2020 BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast grow ... Full text Link to item Cite

FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.

Journal Article Nat Rev Nephrol · January 2020 Fibroblast growth factor 23 (FGF23) was initially characterized as an important regulator of phosphate and calcium homeostasis. New research advances demonstrate that FGF23 is also linked to iron economy, inflammation and erythropoiesis. These advances hav ... Full text Link to item Cite

A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial.

Journal Article J Am Soc Nephrol · January 2020 BACKGROUND: Oral sodium bicarbonate (NaHCO3) may preserve kidney function in CKD, even if initiated when serum bicarbonate concentration is normal. Adequately powered trials testing this hypothesis have not been conducted, partly because the best dose for ... Full text Link to item Cite

Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: The Northern Manhattan Study.

Journal Article PLoS One · 2020 BACKGROUND: Estimated glomerular filtration rate (eGFR) is routinely utilized as a measure of renal function. While creatinine-based eGFR (eGFRcr) is widely used in clinical practice, the use of cystatin-C to estimate GFR (eGFRcys) has demonstrated superio ... Full text Link to item Cite

Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.

Journal Article Am J Kidney Dis · December 2019 RATIONALE & OBJECTIVE: An elevated fibroblast growth factor 23 (FGF-23) level is independently associated with adverse outcomes in populations with chronic kidney disease, but it is unknown whether FGF-23 testing can improve clinical risk prediction in ind ... Full text Link to item Cite

Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.

Journal Article Kidney Int · December 2019 Iron deficiency, anemia, hyperphosphatemia, and increased fibroblast growth factor 23 (FGF23) are common and interrelated complications of chronic kidney disease (CKD) that are linked to CKD progression, cardiovascular disease and death. Ferric citrate is ... Full text Link to item Cite

Does a rise in plasma erythropoietin after high-altitude exposure affect FGF23 in healthy volunteers on a normal or low-phosphorus diet?

Journal Article Nutr Metab Cardiovasc Dis · December 2019 BACKGROUND AND AIMS: Data of experimental rodent models suggest that hypoxia with subsequent increase in erythropoietin stimulates the expression of the phosphaturic hormone fibroblast growth factor 23 (FGF23). METHODS AND RESULTS: To translate the finding ... Full text Link to item Cite

Vitamin D Metabolic Ratio and Risks of Death and CKD Progression.

Journal Article Kidney Int Rep · November 2019 INTRODUCTION: Assessment of impaired vitamin D metabolism is limited by lack of functional measures. CYP24A1-mediated vitamin D clearance, calculated as the ratio of serum 24,25-dihydroxyvitamin D3 to 25-hydroxyvitamin D3 (the vitamin D metabolic ratio, VD ... Full text Link to item Cite

FGFR4 does not contribute to progression of chronic kidney disease.

Journal Article Sci Rep · October 1, 2019 In chronic kidney disease (CKD), elevated serum levels of the phosphate regulating hormone fibroblast growth factor (FGF) 23 have emerged as powerful risk factors for cardiovascular disease and death. Mechanistically, FGF23 can bind and activate fibroblast ... Full text Link to item Cite

Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study.

Journal Article J Am Heart Assoc · August 6, 2019 Background We tested associations of cardiac biomarkers of myocardial stretch, injury, inflammation, and fibrosis with the risk of incident atrial fibrillation (AF) in a prospective study of chronic kidney disease patients. Methods and Results The study sa ... Full text Link to item Cite

Predictors of Net Acid Excretion in the Chronic Renal Insufficiency Cohort (CRIC) Study.

Journal Article Am J Kidney Dis · August 2019 RATIONALE & OBJECTIVE: Higher urine net acid excretion (NAE) is associated with slower chronic kidney disease progression, particularly in patients with diabetes mellitus. To better understand potential mechanisms and assess modifiable components, we explo ... Full text Link to item Cite

A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.

Journal Article Journal of the American Society of Nephrology : JASN · August 2019 BackgroundResearchers have yet to determine the optimal care of patients with advanced CKD. Evidence suggests that anemia and CKD-related disordered mineral metabolism (including abnormalities in phosphate and fibroblast growth factor 23 [FGF23]) ... Full text Cite

Association of Fitness With Racial Differences in Chronic Kidney Disease.

Journal Article Am J Prev Med · July 2019 INTRODUCTION: Non-white minorities are at higher risk for chronic kidney disease than non-Hispanic whites. Better cardiorespiratory fitness is associated with slower declines in estimated glomerular filtration rate and a lower incidence of chronic kidney d ... Full text Link to item Cite

Global Health Training Opportunities in North American Nephrology Fellowships

Journal Article Kidney International Reports · July 1, 2019 Full text Cite

Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study.

Journal Article Sci Rep · June 20, 2019 Ferric citrate hydrate (FC) is an iron-based phosphate binder approved for hyperphosphataemia in patients with chronic kidney disease. We conducted a randomised controlled trial to evaluate the effects of FC on anaemia management in haemodialysis patients ... Full text Link to item Cite

Modifiers of Plasma 25-Hydroxyvitamin D and Chronic Kidney Disease Outcomes in Black Americans: The Jackson Heart Study.

Internet Publication · June 1, 2019 BACKGROUND: 25-hydroxyvitamin D [25(OH)D] is lower in black compared with white Americans but is not consistently associated with outcomes in this group, possibly due to genetic and other biological differences. We examined the association of plasma 25(OH) ... Full text Open Access Link to item Cite

Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Journal Article Am J Kidney Dis · June 2019 RATIONALE & OBJECTIVE: Coronary artery calcification (CAC) is prevalent among patients with chronic kidney disease (CKD) and increases risks for cardiovascular disease events and mortality. We hypothesized that a novel serum measure of calcification propen ... Full text Link to item Cite

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Journal Article J Am Soc Nephrol · June 2019 BACKGROUND: Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels may be modifiable to prevent cardiovascular disease in CKD. Short-term studies have reported modest efficacy in phosphate and FGF23 reduction with intestinal phosphate binder ... Full text Link to item Cite

Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study.

Journal Article Am J Kidney Dis · March 2019 RATIONALE & OBJECTIVE: Traditional risk estimates for atherosclerotic vascular disease (ASVD) and death may not perform optimally in the setting of chronic kidney disease (CKD). We sought to determine whether the addition of measures of inflammation and ki ... Full text Link to item Cite

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.

Journal Article Nephrol Dial Transplant · February 1, 2019 BACKGROUND: Elevated serum fibroblast growth factor 23 (FGF23) is strongly associated with cardiovascular risk and mortality. Tenapanor, an inhibitor of gastrointestinal sodium/hydrogen exchanger isoform 3, decreased serum phosphate in a randomized, double ... Full text Link to item Cite

Good Guys, Bad Guys, Guesses, and Near Misses in Nephrology.

Journal Article Clin J Am Soc Nephrol · January 7, 2019 Full text Link to item Cite

Health Behaviors in Younger and Older Adults With CKD: Results From the CRIC Study.

Journal Article Kidney Int Rep · January 2019 INTRODUCTION: A cornerstone of kidney disease management is participation in guideline-recommended health behaviors. However, the relationship of these health behaviors with outcomes, and the identification of barriers to health behavior engagement, have n ... Full text Link to item Cite

Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study.

Journal Article Am J Nephrol · 2019 BACKGROUND: Long-term patterns of fibroblast growth factor 23 (FGF23) are poorly characterized among dialysis patients. OBJECTIVES: To identify different FGF23 trajectories and determine clinical factors that predict distinct FGF23 trajectories and whether ... Full text Link to item Cite

Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study.

Journal Article Am J Hypertens · January 1, 2019 BACKGROUND: Higher fibroblast growth factor-23 (FGF23) concentrations have been found to be associated with incident heart failure (HF). Experimental data suggest FGF23 directly stimulates myocardial hypertrophy. FGF23 may also enhance renin-angiotensin-al ... Full text Link to item Cite

DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease.

Journal Article Bone Res · 2019 During chronic kidney disease (CKD), alterations in bone and mineral metabolism include increased production of the hormone fibroblast growth factor 23 (FGF23) that may contribute to cardiovascular mortality. The osteocyte protein dentin matrix protein 1 ( ... Full text Link to item Cite

GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease.

Journal Article Am J Nephrol · 2019 BACKGROUND: In the majority of patients with advanced chronic kidney disease (CKD), values of parathyroid hormone (PTH1-84) and fibroblast growth factor 23 (FGF-23) exceed the normal reference range, potentially as an appropriate adaptation to reduced glom ... Full text Link to item Cite

Randomized trial of intravenous iron-induced hypophosphatemia.

Journal Article JCI Insight · December 6, 2018 BACKGROUND: Hypophosphatemia can complicate intravenous iron therapy, but no head-to-head trials compared the effects of newer intravenous iron formulations on risks and mediators of hypophosphatemia. METHODS: In a randomized, double-blinded, controlled tr ... Full text Link to item Cite

Chicago supermarket data and food access analytics in census tract shapefiles for 2007-2014.

Journal Article Data Brief · December 2018 Longitudinal analysis of supermarkets over time is essential to understanding the dynamics of foodscape environments for healthy living. Supermarkets for 2007, 2011, and 2014 for the City of Chicago were curated and further validated. The average distance ... Full text Open Access Link to item Cite

Genetic Variants Associated with Circulating Fibroblast Growth Factor 23.

Journal Article J Am Soc Nephrol · October 2018 BACKGROUND: Fibroblast growth factor 23 (FGF23), a bone-derived hormone that regulates phosphorus and vitamin D metabolism, contributes to the pathogenesis of mineral and bone disorders in CKD and is an emerging cardiovascular risk factor. Central elements ... Full text Link to item Cite

Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos.

Journal Article Bone · September 2018 Preclinical data suggest that hypoxia stimulates fibroblast growth factor 23 (FGF23) transcription and cleavage in osteocytes, resulting in elevated circulating c-terminal (cFGF23) levels but normal intact FGF23 (iFGF23) levels. We conducted a case-control ... Full text Link to item Cite

Metabolic Changes with Base-Loading in CKD.

Journal Article Clin J Am Soc Nephrol · August 7, 2018 Full text Open Access Link to item Cite

Genetic background influences cardiac phenotype in murine chronic kidney disease.

Conference Nephrol Dial Transplant · July 1, 2018 BACKGROUND: Levels of fibroblast growth factor 23 (FGF23) increase early in chronic kidney disease (CKD) and are independently associated with left ventricular hypertrophy (LVH), heart failure and death. Experimental models of CKD with elevated FGF23 and L ... Full text Link to item Cite

FGF23 (Fibroblast Growth Factor-23) and Incident Hypertension in Young and Middle-Aged Adults: The CARDIA Study.

Journal Article Hypertension · July 2018 Blacks have the highest prevalence of hypertension in the United States. Higher levels of FGF23 (fibroblast growth factor-23) have been associated with worse cardiovascular outcomes. Whether FGF23 is associated with rising blood pressure (BP) and racial di ... Full text Link to item Cite

Urban foodscape trends: Disparities in healthy food access in Chicago, 2007-2014.

Journal Article Health Place · July 2018 We investigated changes in supermarket access in Chicago between 2007 and 2014, spanning The Great Recession, which we hypothesized worsened local food inequity. We mapped the average street network distance to the nearest supermarket across census tracts ... Full text Link to item Cite

Incidence and Progression of Chronic Kidney Disease in Black and White Individuals with Type 2 Diabetes.

Journal Article Clin J Am Soc Nephrol · June 7, 2018 BACKGROUND AND OBJECTIVES: Type 2 diabetes and associated CKD disproportionately affect blacks. It is uncertain if racial disparities in type 2 diabetes-associated CKD are driven by biologic factors that influence propensity to CKD or by differences in typ ... Full text Link to item Cite

Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients.

Journal Article Clin J Am Soc Nephrol · April 6, 2018 BACKGROUND AND OBJECTIVES: Dysregulated mineral metabolism is a common and potentially maladaptive feature of critical illness, especially in patients with AKI, but its association with death has not been comprehensively investigated. We sought to determin ... Full text Link to item Cite

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide.

Journal Article Kidney Int Rep · March 2018 INTRODUCTION: A recent study suggested that orally dosed ferric citrate hydrate (FC) corrects renal anemia in patients on hemodialysis (HD), suggesting biological differences in effects of iron supplementation using different routes of administration. To a ... Full text Link to item Cite

Longitudinal FGF23 Trajectories and Mortality in Patients with CKD.

Journal Article J Am Soc Nephrol · February 2018 Elevated fibroblast growth factor 23 (FGF23) levels, measured at a single time, are strongly associated with increased risk of mortality in patients with CKD. There are minimal data on serial FGF23 measurements in CKD. In a prospective case-cohort study of ... Full text Link to item Cite

FGF23 and Left Ventricular Hypertrophy in Children with CKD.

Journal Article Clin J Am Soc Nephrol · January 6, 2018 BACKGROUND AND OBJECTIVES: High plasma concentration of fibroblast growth factor 23 (FGF23) is a risk factor for left ventricular hypertrophy (LVH) in adults with CKD, and induces myocardial hypertrophy in experimental CKD. We hypothesized that high FGF23 ... Full text Link to item Cite

Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study.

Journal Article PLoS One · 2018 BACKGROUND: Accurate glomerular filtration rate estimation informs drug dosing and risk stratification. Body composition heterogeneity influences creatinine production and the precision of creatinine-based estimated glomerular filtration rate (eGFRcr) in t ... Full text Open Access Link to item Cite

Fibroblast growth factor23 is associated with axonal integrity and neural network architecture in the human frontal lobes.

Journal Article PLoS One · 2018 Elevated levels of FGF23 in individuals with chronic kidney disease (CKD) are associated with adverse health outcomes, such as increased mortality, large vessel disease, and reduced white matter volume, cardiovascular and cerebrovascular events. Apart from ... Full text Open Access Link to item Cite

A Patient With CKD Develops Cholestatic Liver Injury During a Clinical Trial

Journal Article Kidney International Reports · January 1, 2018 Full text Cite

Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study.

Journal Article J Clin Endocrinol Metab · December 1, 2017 CONTEXT: Mineral and bone disorders (MBDs) might be relevant in the etiology of infection. OBJECTIVE: To determine whether MBD biomarkers were associated with the incidence of hospitalization with infection. We also assessed the cross-sectional association ... Full text Link to item Cite

Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study.

Journal Article Clin J Am Soc Nephrol · November 7, 2017 BACKGROUND AND OBJECTIVES: Anemia is an early complication of CKD that is associated with increased morbidity and mortality. Prior data show associations between abnormal mineral metabolism markers and decreased erythropoiesis. However, few studies have in ... Full text Link to item Cite

Dietary factors and fibroblast growth factor-23 levels in young adults with African ancestry.

Journal Article J Bone Miner Metab · November 2017 Fibroblast growth factor-23 (FGF23), a phosphaturic hormone secreted mainly by osteocytes, maintains serum phosphate levels within a tight range by promoting phosphaturia. Previous studies have mainly focused on the link between FGF23 levels and dietary in ... Full text Link to item Cite

Acid Load and Phosphorus Homeostasis in CKD.

Journal Article Am J Kidney Dis · October 2017 BACKGROUND: The kidneys maintain acid-base homeostasis through excretion of acid as either ammonium or as titratable acids that primarily use phosphate as a buffer. In chronic kidney disease (CKD), ammoniagenesis is impaired, promoting metabolic acidosis. ... Full text Link to item Cite

Effects of Vitamin D2 Supplementation on Vitamin D3 Metabolism in Health and CKD.

Journal Article Clin J Am Soc Nephrol · September 7, 2017 BACKGROUND AND OBJECTIVES: Vitamin D supplements are prescribed to correct low circulating concentrations of 25-hydroxyvitamin D. In CKD, vitamin D metabolism is complicated by decreased conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D by CYP27 ... Full text Link to item Cite

Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Journal Article Clin J Am Soc Nephrol · September 7, 2017 BACKGROUND AND OBJECTIVES: Increases in fibroblast growth factor 23 precede kidney function decline in autosomal dominant polycystic kidney disease; however, the role of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease has not be ... Full text Link to item Cite

Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis.

Journal Article Nephrol Dial Transplant · September 1, 2017 BACKGROUND: Patients undergoing hemodialysis and kidney graft recipients are high-risk populations for cardiovascular and all-cause mortality. Fibroblast growth factor 23 (FGF23), osteoprotegerin (OPG), RANK ligand, osteopontin (OPN), Klotho protein and bo ... Full text Link to item Cite

FGF23 and Nutritional Metabolism.

Book · August 21, 2017 The discovery of fibroblast growth factor 23 (FGF23) has provided a more complete understanding of the regulation of phosphate and mineral homeostasis in health and in chronic kidney disease. It has also offered new insights into stratification of risk of ... Full text Link to item Cite

Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort.

Journal Article Am J Hypertens · August 1, 2017 BACKGROUND: Chronic kidney disease (CKD) is associated with increased risk of cardiovascular disease (CVD) and it is especially common among Blacks. Left ventricular hypertrophy (LVH) is an important subclinical marker of CVD, but there are limited data on ... Full text Link to item Cite

Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks.

Journal Article Clin J Am Soc Nephrol · July 7, 2017 Survival analysis is commonly used to evaluate factors associated with time to an event of interest (e.g., ESRD, cardiovascular disease, and mortality) among CKD populations. Time to the event of interest is typically observed only for some participants. O ... Full text Link to item Cite

Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis.

Journal Article Am J Physiol Lung Cell Mol Physiol · July 1, 2017 Alveolar epithelial cell (AEC) apoptosis and inadequate repair resulting from "exaggerated" lung aging and mitochondrial dysfunction are critical determinants promoting lung fibrosis. α-Klotho, which is an antiaging molecule that is expressed predominantly ... Full text Link to item Cite

Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease.

Journal Article JAMA Cardiol · June 1, 2017 IMPORTANCE: Coronary artery calcification (CAC) is highly prevalent in dialysis-naive patients with chronic kidney disease (CKD). However, there are sparse data on the association of CAC with subsequent risk of cardiovascular disease and all-cause mortalit ... Full text Link to item Cite

Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness.

Journal Article J Am Soc Nephrol · June 2017 Elevated plasma levels of the osteocyte-derived hormone fibroblast growth factor 23 (FGF23) have emerged as a powerful biomarker of cardiovascular disease and death in patients with CKD. Whether elevated urinary or plasma FGF23 levels are prospectively ass ... Full text Link to item Cite

The Authors Reply.

Journal Article Kidney Int · June 2017 Full text Link to item Cite

Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Journal Article J Am Heart Assoc · May 17, 2017 BACKGROUND: Heart failure is common in patients with chronic kidney disease. We studied risk factors for incident heart failure among 3557 participants in the CRIC (Chronic Renal Insufficiency Cohort) Study. METHODS AND RESULTS: Kidney function was assesse ... Full text Open Access Link to item Cite

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.

Journal Article Sci Rep · May 16, 2017 Fibroblast growth factor (FGF) 23 is a phosphaturic hormone that directly targets cardiac myocytes via FGF receptor (FGFR) 4 thereby inducing hypertrophic myocyte growth and the development of left ventricular hypertrophy (LVH) in rodents. Serum FGF23 leve ... Full text Open Access Link to item Cite

Genetic Variants Associated with Circulating Parathyroid Hormone.

Journal Article J Am Soc Nephrol · May 2017 Parathyroid hormone (PTH) is a primary calcium regulatory hormone. Elevated serum PTH concentrations in primary and secondary hyperparathyroidism have been associated with bone disease, hypertension, and in some studies, cardiovascular mortality. Genetic c ... Full text Link to item Cite

Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.

Journal Article Kidney Int · March 2017 Inflammation is a consequence of chronic kidney disease (CKD) and is associated with adverse outcomes in many clinical settings. Inflammation stimulates production of fibroblast growth factor 23 (FGF23), high levels of which are independently associated wi ... Full text Link to item Cite

Serum levels of fibroblast growth factor 23 are elevated in patients with active Lupus nephritis.

Journal Article Cytokine · March 2017 BACKGROUND: Fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone is an established cardiovascular risk factor. Recently, FGF23 has been related to inflammation. Lupus is an inflammatory disease, and whether FGF23 is associated with Lupus nep ... Full text Link to item Cite

Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes.

Journal Article Kidney Int · January 2017 Higher diet-dependent nonvolatile acid load is associated with faster chronic kidney disease (CKD) progression, but most studies have used estimated acid load or measured only components of the gold standard, net acid excretion (NAE). Here we measured NAE ... Full text Link to item Cite

Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.

Journal Article Clin J Am Soc Nephrol · November 7, 2016 BACKGROUND AND OBJECTIVES: Plasma fibroblast growth factor 23 (FGF23) concentrations increase early in the course of CKD in children. High FGF23 levels associate with progression of CKD in adults. Whether FGF23 predicts CKD progression in children is unkno ... Full text Link to item Cite

Asymptomatic ventricular arrhythmia and clinical outcomes in chronic kidney disease: A pilot study

Journal Article CardioRenal Medicine · November 1, 2016 Background/Aims: Ventricular arrhythmia is associated with increased risk of cardiovascular events and death in the general population. Sudden death is a leading cause of death in end-stage renal disease. We aimed at evaluating the effects of ventricular a ... Full text Cite

Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.

Journal Article Kidney Int · November 2016 Patients with chronic kidney disease (CKD) develop increased levels of the phosphate-regulating hormone, fibroblast growth factor (FGF) 23, that are associated with a higher risk of mortality. Increases in inflammatory markers are another common feature th ... Full text Link to item Cite

Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study.

Journal Article J Clin Endocrinol Metab · October 2016 CONTEXT: An elevated fibroblast growth factor (FGF) 23 is an independent risk factor for cardiovascular disease and mortality in patients with kidney disease. The relationship between FGF23 and cause-specific mortality in the general population is unknown. ... Full text Link to item Cite

Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies.

Journal Article Am J Kidney Dis · October 2016 BACKGROUND: Non-Hispanic blacks and Hispanics with end-stage renal disease have a lower risk for death than non-Hispanic whites, but data for racial/ethnic variation in cardiovascular outcomes for non-dialysis-dependent chronic kidney disease are limited. ... Full text Link to item Cite

Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.

Journal Article JAMA Cardiol · August 1, 2016 IMPORTANCE: Levels of fibroblast growth factor 23 (FGF23) are elevated in chronic kidney disease (CKD) and strongly associated with left ventricular hypertrophy, heart failure, and death. Whether FGF23 is an independent risk factor for atrial fibrillation ... Full text Link to item Cite

Atrial Fibrillation and Risk of ESRD in Adults with CKD.

Journal Article Clin J Am Soc Nephrol · July 7, 2016 BACKGROUND AND OBJECTIVES: Atrial fibrillation frequently complicates CKD and is associated with adverse outcomes. Progression to ESRD is a major complication of CKD, but the link with atrial fibrillation has not been fully delineated. In this study, we ex ... Full text Link to item Cite

Mineral metabolism: Progress in the face of complexity

Journal Article Current Opinion in Nephrology and Hypertension · July 1, 2016 Full text Cite

Fibroblast Growth Factor-23 (FGF-23) Levels Differ Across Populations by Degree of Industrialization.

Journal Article J Clin Endocrinol Metab · May 2016 Featured Publication CONTEXT: Compensatory increases in fibroblast growth factor 23 (FGF23) with increasing phosphate intake may adversely impact health. However, population and clinical studies examining the link between phosphate intake and FGF23 levels have focused mainly o ... Full text Link to item Cite

Genetic African Ancestry and Markers of Mineral Metabolism in CKD.

Journal Article Clin J Am Soc Nephrol · April 7, 2016 BACKGROUND AND OBJECTIVES: Disorders of mineral metabolism are more common in African Americans with CKD than in European Americans with CKD. Previous studies have focused on the differences in mineral metabolism by self-reported race, making it difficult ... Full text Link to item Cite

Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study.

Journal Article Stroke · April 2016 Featured Publication BACKGROUND AND PURPOSE: Elevated fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and is linked with mortality, cardiovascular events, and stroke. However, the role of FGF23 as a risk factor for subclinical cerebrovascular damage is uncl ... Full text Link to item Cite

Cord Blood Ferritin and Fibroblast Growth Factor-23 Levels in Neonates.

Journal Article J Clin Endocrinol Metab · April 2016 Featured Publication CONTEXT: Elevated levels of the phosphate-regulating hormone, fibroblast growth factor-23 (FGF-23) are associated with skeletal and cardiovascular disease. Levels of FGF-23 are elevated in neonates, but the mechanisms are poorly understood. Iron deficiency ... Full text Link to item Cite

Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery.

Journal Article Kidney Int · April 2016 Featured Publication Fibroblast growth factor 23 (FGF23) is elevated in chronic kidney disease and associated with increased mortality, but data on FGF23 in humans with acute kidney injury (AKI) are limited. Here we tested whether FGF23 levels rise early in the course of AKI f ... Full text Link to item Cite

The Association Between Conversion to In-centre Nocturnal Hemodialysis and Left Ventricular Mass Regression in Patients With End-Stage Renal Disease.

Journal Article Can J Cardiol · March 2016 BACKGROUND: In-centre nocturnal hemodialysis (INHD, 7-8 hours/session, 3 times/week) is an increasingly utilized form of dialysis intensification, though data on the cardiovascular benefits of this modality are limited. METHODS: In this prospective cohort ... Full text Link to item Cite

Pruning the ricket thicket.

Journal Article J Clin Invest · February 2016 Overexpression of FGF23 results in hypophosphatemic rickets, which is characterized by renal phosphate wasting, inappropriately low circulating levels of the active form of vitamin D, and skeletal abnormalities. The precise mechanisms of how excess FGF23 l ... Full text Link to item Cite

A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.

Conference Transplantation · January 2016 BACKGROUND: Kidney transplantation corrects or improves many complications of chronic kidney disease, but its impact on disordered mineral metabolism is incompletely understood. METHODS: We performed a multicenter, prospective, observational cohort study o ... Full text Link to item Cite

Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production.

Journal Article Kidney Int · January 2016 Circulating levels of fibroblast growth factor 23 (FGF23) are elevated in patients with chronic kidney disease (CKD), but the mechanisms are poorly understood. Here we tested whether inflammation and iron deficiency regulate FGF23. In wild-type mice, acute ... Full text Link to item Cite

Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.

Journal Article Clin J Am Soc Nephrol · December 7, 2015 BACKGROUND AND OBJECTIVES: Common apolipoprotein L1 (APOL1) variants are associated with increased risk of progressive CKD; however, not all individuals with high-risk APOL1 variants experience CKD progression. Identification of factors contributing to het ... Full text Link to item Cite

Food Access, Chronic Kidney Disease, and Hypertension in the U.S.

Journal Article Am J Prev Med · December 2015 INTRODUCTION: Greater distance to full-service supermarkets and low income may impair access to healthy diets and contribute to chronic kidney disease (CKD) and hypertension. The study aim was to determine relationships among residence in a "food desert," ... Full text Link to item Cite

Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

Journal Article Cell Metab · December 1, 2015 Chronic kidney disease (CKD) is a worldwide public health threat that increases risk of death due to cardiovascular complications, including left ventricular hypertrophy (LVH). Novel therapeutic targets are needed to design treatments to alleviate the card ... Full text Link to item Cite

Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014.

Journal Article Clin J Am Soc Nephrol · October 7, 2015 In the short time since its initial discovery as the cause of rare hypophosphatemic disorders, fibroblast growth factor-23 (FGF-23) has emerged as a major regulator of mineral metabolism and critical component of the bone and mineral adaptation to CKD. How ... Full text Link to item Cite

Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Journal Article J Am Soc Nephrol · October 2015 Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet available therapies only modestly improve clinical outcomes. Observational studies report independent associations between elevated serum phosphate and fibroblast growth ... Full text Link to item Cite

Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.

Journal Article Nephrol Dial Transplant · September 2015 BACKGROUND: Elevated circulating concentrations of phosphate and fibroblast growth factor 23 (FGF23) contribute to the pathogenesis of cardiovascular disease in chronic kidney disease (CKD). Retinopathy is a common manifestation of microvascular disease in ... Full text Link to item Cite

Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study.

Journal Article Arterioscler Thromb Vasc Biol · September 2015 OBJECTIVE: Elevated fibroblast growth factor 23 (FGF23), a hormone that regulates phosphate homeostasis, has been associated with mortality, cardiovascular events, and stroke, and to arterial calcification in chronic kidney disease, but its role in atheros ... Full text Link to item Cite

When there will never be a randomized controlled trial.

Journal Article Kidney Int · August 2015 There are many unanswered questions about how to manage secondary hyperparathyroidism and associated alterations in mineral metabolism in patients with end-stage renal disease. We provide commentary on an observational study by Komaba et al. that presents ... Full text Link to item Cite

Serum Phosphorus and Progression of CKD and Mortality: A Meta-analysis of Cohort Studies.

Journal Article Am J Kidney Dis · August 2015 BACKGROUND: Recent studies have indicated that phosphorus may play an independent pathogenic role in chronic kidney disease (CKD) progression, but some of those studies were underpowered and yielded inconsistent results. STUDY DESIGN: Systematic review and ... Full text Link to item Cite

Bones and stones, edition 2015.

Journal Article Curr Opin Nephrol Hypertens · July 2015 Full text Link to item Cite

Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.

Journal Article J Am Soc Nephrol · June 2015 Cardiac dysfunction in CKD is characterized by aberrant cardiac remodeling with hypertrophy and fibrosis. CKD is a state of severe systemic Klotho deficiency, and restoration of Klotho attenuates vascular calcification associated with CKD. We examined the ... Full text Link to item Cite

A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

Journal Article Am J Kidney Dis · May 2015 BACKGROUND: Iron deficiency anemia and serum phosphate levels > 4.0mg/dL are relatively common in chronic kidney disease stages 3 to 5 and are associated with higher risks of progressive loss of kidney function, cardiovascular events, and mortality. STUDY ... Full text Link to item Cite

Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study.

Journal Article J Am Heart Assoc · April 20, 2015 BACKGROUND: Serum bicarbonate varies over time in chronic kidney disease (CKD) patients, and this variability may portend poor cardiovascular outcomes. The aim of this study was to conduct a time-updated longitudinal analysis to evaluate the association of ... Full text Open Access Link to item Cite

Impact of westernization on fibroblast growth factor 23 levels among individuals of African ancestry.

Journal Article Nephrol Dial Transplant · April 2015 INTRODUCTION: The Western diet is associated with high consumption of processed foods preserved with phosphate. Higher dietary phosphate consumption stimulates production of fibroblast growth factor 23 (FGF23), which heightens risk for cardiovascular disea ... Full text Link to item Cite

High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study.

Journal Article J Am Soc Nephrol · April 2015 High-sensitivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) strongly predict heart failure (HF) in the general population. However, the interpretation of levels of these biomarkers as predictors of HF is uncertain among pa ... Full text Link to item Cite

Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial.

Journal Article Circulation · January 20, 2015 BACKGROUND: A large body of epidemiological and experimental evidence suggests that vitamin D deficiency may promote hypertension. This raises the possibility that vitamin D supplementation could be a simple intervention to reduce blood pressure, but data ... Full text Link to item Cite

Fibroblast growth factor 23 and incident CKD in type 2 diabetes.

Journal Article Clin J Am Soc Nephrol · January 7, 2015 BACKGROUND AND OBJECTIVES: High levels of fibroblast growth factor 23 are associated with accelerated progression of CKD. Whether high fibroblast growth factor 23 levels also predict incident CKD is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: ... Full text Link to item Cite

The biomarker niche for fibroblast growth factor 23 testing in CKD.

Journal Article J Am Soc Nephrol · January 2015 Featured Publication Full text Link to item Cite

Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.

Journal Article Nephrol Dial Transplant · November 2014 BACKGROUND: Activation of fibroblast growth factor receptor (FGFR)-dependent signalling by FGF23 may contribute to the complex pathogenesis of left ventricular hypertrophy (LVH) in chronic kidney disease (CKD). Pan FGFR blockade by PD173074 prevented devel ... Full text Link to item Cite

In search of the fountain of youth.

Journal Article J Am Soc Nephrol · October 2014 Featured Publication Full text Link to item Cite

Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study.

Journal Article Rheumatology (Oxford) · September 2014 OBJECTIVE: Nephrogenic systemic fibrosis (NSF) is an iatrogenic fibrosing disorder that primarily affects individuals with chronic kidney disease (CKD) following exposure to gadolinium-based contrast agents (GBCAs). Derangements of calcium and phosphorus h ... Full text Link to item Cite

The pursuit of truth and beauty.

Journal Article Curr Opin Nephrol Hypertens · July 2014 Full text Link to item Cite

Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.

Journal Article Curr Opin Nephrol Hypertens · July 2014 PURPOSE OF REVIEW: High levels of fibroblast growth factor 23 (FGF23) cause the rare disorders of hypophosphatemic rickets and are a risk factor for cardiovascular disease and death in patients with chronic kidney disease (CKD). Despite major advances in u ... Full text Link to item Cite

Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS).

Journal Article Neurology · May 13, 2014 OBJECTIVE: To examine fibroblast growth factor 23 (FGF23) as a risk factor for incident stroke in a racially/ethnically diverse population-based urban cohort. METHODS: Stroke-free Northern Manhattan Study participants with FGF23 measurements (n = 2,525) we ... Full text Link to item Cite

Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Journal Article Nat Rev Nephrol · May 2014 Disturbances in phosphate homeostasis are common in patients with chronic kidney disease. As kidney function declines, circulating concentrations of phosphate and the phosphate-regulatory hormone, fibroblast growth factor (FGF)-23, rise progressively. High ... Full text Link to item Cite

Increasing use of vitamin D supplementation in the chronic renal insufficiency cohort study.

Journal Article J Ren Nutr · May 2014 OBJECTIVE: This study examined rates and determinants of vitamin D supplementation among Chronic Renal Insufficiency Cohort (CRIC) participants and determined the association between dose and 25-hydroxyvitamin D (25(OH)D) level. The 2010 Institute of Medic ... Full text Link to item Cite

Fibroblast growth factor-23 and cardiovascular events in CKD.

Journal Article J Am Soc Nephrol · February 2014 An elevated level of fibroblast growth factor-23 (FGF-23) is the earliest abnormality of mineral metabolism in CKD. High FGF-23 levels promote left ventricular hypertrophy but not coronary artery calcification. We used survival analysis to determine whethe ... Full text Link to item Cite

Correlates of left ventricular mass in chronic hemodialysis recipients.

Journal Article Int J Cardiovasc Imaging · February 2014 We aimed to clarify the correlates of left ventricular mass and secondarily, left ventricular volume, in a cohort of prevalent hemodialysis recipients. Left ventricular hypertrophy is common and left ventricular mass is a widely-accepted surrogate for clin ... Full text Link to item Cite

Disordered FGF23 and mineral metabolism in children with CKD.

Journal Article Clin J Am Soc Nephrol · February 2014 BACKGROUND AND OBJECTIVES: In children with CKD, information is limited regarding the prevalence and determinants of fibroblast growth factor 23 excess and 1,25-dihyroxyvitamin D deficiency across the spectrum of predialysis CKD. This study characterized c ... Full text Link to item Cite

Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease

Journal Article Nature Reviews Nephrology · January 1, 2014 Disturbances in phosphate homeostasis are common in patients with chronic kidney disease. As kidney function declines, circulating concentrations of phosphate and the phosphate-regulatory hormone, fibroblast growth factor (FGF)-23, rise progressively. High ... Full text Cite

Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC).

Journal Article BMC Nephrol · October 22, 2013 BACKGROUND: Cardiac troponin T is independently associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD). Serum levels of high sensitivity cardiac troponin T (hs-TnT) reflect subclinical myocardial injury in ambulat ... Full text Link to item Cite

Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.

Journal Article Am J Kidney Dis · October 2013 BACKGROUND: The purpose of this study is to evaluate serum bicarbonate level as a risk factor for renal outcomes, cardiovascular events, and mortality in patients with chronic kidney disease (CKD). STUDY DESIGN: Observational cohort study. SETTING & PARTIC ... Full text Link to item Cite

Plasma FGF23 levels increase rapidly after acute kidney injury.

Journal Article Kidney Int · October 2013 Emerging evidence suggests that fibroblast growth factor 23 (FGF23) levels are elevated in patients with acute kidney injury (AKI). In order to determine how early this increase occurs, we used a murine folic acid-induced nephropathy model and found that p ... Full text Link to item Cite

Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes.

Journal Article Clin Endocrinol (Oxf) · October 2013 OBJECTIVE: Numerous studies have evaluated the prevalence and importance of vitamin D deficiency among patients with chronic kidney disease and end-stage renal disease; however, little is known about vitamin D levels in acute kidney injury (AKI). We evalua ... Full text Link to item Cite

Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation.

Journal Article Am J Kidney Dis · September 2013 Chronic kidney disease (CKD)-mineral and bone disorder is associated with diverse metabolic and endocrine disturbances that ultimately may contribute to further loss of kidney function, bone demineralization, and fatal or nonfatal cardiovascular events. Re ... Full text Link to item Cite

Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.

Journal Article J Bone Miner Res · August 2013 Fibroblast growth factor 23 (FGF23) is an osteocyte-derived hormone that regulates phosphate and vitamin D homeostasis. Through unknown mechanisms, certain intravenous iron preparations induce acute, reversible increases in circulating FGF23 levels that lo ... Full text Link to item Cite

Innovations in bones and stones.

Journal Article Curr Opin Nephrol Hypertens · July 2013 Full text Link to item Cite

Catastrophic antiphospholipid syndrome with concurrent thrombotic and hemorrhagic manifestations.

Journal Article Lupus · July 2013 Antiphospholipid syndrome (APS) is a distinct autoimmune prothrombotic disorder due to pathogenic autoantibodies directed against proteins that bind to phospholipids. APS is characterized by arterial and venous thrombosis and their clinical sequelae. Catas ... Full text Open Access Cite

FGF23 modifies the relationship between vitamin D and cardiac remodeling.

Journal Article Circ Heart Fail · July 2013 BACKGROUND: There is growing evidence to support an important role for vitamin D and related hormones, parathyroid hormone and fibroblast growth factor 23 (FGF23), on cardiac remodeling in chronic kidney disease. Our objective was to determine the relation ... Full text Link to item Cite

Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.

Journal Article Kidney Int · June 2013 Elevated fibroblast growth factor 23 (FGF23) is associated with cardiovascular disease in patients with chronic kidney disease. As a potential mediating mechanism, FGF23 induces left ventricular hypertrophy; however, its role in arterial calcification is l ... Full text Open Access Link to item Cite

Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.

Journal Article Clin J Am Soc Nephrol · June 2013 BACKGROUND: Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate intake or absorption may decrease FGF23 levels, but data on the combined effects of d ... Full text Link to item Cite

A physiologic-based approach to the evaluation of a patient with hyperphosphatemia.

Journal Article Am J Kidney Dis · February 2013 Phosphate is required for skeletal mineralization, cellular energy regulation, synthesis of cell membranes and nucleic acids, and a variety of cell signaling pathways. Extracellular serum phosphate concentration is determined by the balance of gastrointest ... Full text Link to item Cite

Mineral metabolites and CKD progression in African Americans.

Journal Article J Am Soc Nephrol · January 2013 CKD progresses more rapidly to ESRD among African Americans compared with Caucasians. Disordered mineral metabolism is more severe among African Americans with CKD, which might partially explain the accelerated progression of their kidney disease. Here, us ... Full text Link to item Cite

Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation.

Journal Article Am J Transplant · January 2013 Data on long-term outcomes of users of inhibitors of the mammalian target of rapamycin (mTORI) are lacking in kidney transplantation. In an analysis of 139 370 US kidney transplant recipients between 1999 through 2010, we compared clinical outcomes among u ... Full text Link to item Cite

Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD.

Journal Article Am J Kidney Dis · January 2013 BACKGROUND: Detectable levels of cardiac troponins are common in individuals with chronic kidney disease (CKD), even in the absence of symptomatic cardiovascular disease. Abnormal cardiac troponin values are associated with coronary artery disease and left ... Full text Link to item Cite

A balanced view of calcium and phosphate homeostasis in chronic kidney disease

Journal Article Kidney International · January 1, 2013 The association of abnormalities of calcium and phosphate homeostasis with adverse clinical outcomes in chronic kidney disease (CKD) has generated interest in developing therapeutic strategies to target mineral metabolism early in the course of CKD. Hill e ... Full text Cite

Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease.

Journal Article J Ren Nutr · January 2013 OBJECTIVE: Elevated serum phosphate concentrations are established risk factors for cardiovascular disease and mortality in chronic kidney disease (CKD). Independent associations of other indices of phosphorus metabolism, such as phosphorus intake, urinary ... Full text Link to item Cite

Expression of fgf23 and αklotho in developing embryonic tissues and adult kidney of the zebrafish, Danio rerio.

Journal Article Nephrol Dial Transplant · December 2012 Fibroblast growth factor 23 (FGF23) is an endocrine hormone that is secreted by bone and acts on the kidney and parathyroid glands to regulate phosphate homeostasis. The effects of FGF23 on phosphate homeostasis are mediated by binding to FGF receptors and ... Full text Link to item Cite

αKlotho: FGF23 coreceptor and FGF23-regulating hormone.

Journal Article J Clin Invest · December 2012 Low levels of phosphate can disrupt bone ossification and predispose to fractures. FGF23 is one of the major determinants of phosphate homeostasis, acting to increase urinary phosphate excretion. However, the regulation of FGF23 is incompletely understood. ... Full text Link to item Cite

Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years.

Journal Article Am J Transplant · December 2012 Simultaneous pancreas kidney transplantation (SPKT) is the treatment of choice for patients with type 1 diabetes and end-stage renal disease. Rapamycin and mycophenolate mofetil (MMF) have been used for maintenance immunosuppression with tacrolimus in SPKT ... Full text Link to item Cite

Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes.

Journal Article JAMA · November 14, 2012 CONTEXT: Lower serum 25-hydroxyvitamin D concentrations are associated with greater risks of many chronic diseases across large, prospective community-based studies. Substrate 25-hydroxyvitamin D must be converted to 1,25-dihydroxyvitamin D for full biolog ... Full text Link to item Cite

Partial answers from partial Klotho deficiency.

Journal Article J Am Soc Nephrol · October 2012 Full text Link to item Cite

Update on fibroblast growth factor 23 in chronic kidney disease.

Journal Article Kidney Int · October 2012 Chronic kidney disease (CKD) is a public health epidemic that affects millions of people worldwide. Presence of CKD predisposes individuals to high risks of end-stage renal disease (ESRD), cardiovascular disease, and premature death. Disordered phosphate h ... Full text Link to item Cite

Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome.

Journal Article Clin Chem · September 2012 BACKGROUND: Quantification and comparison of high-sensitivity (hs) cardiac troponin I (cTnI) and cTnT concentrations in chronic kidney disease (CKD) have not been reported. We examined the associations between hs cTnI and cTnT, cardiovascular disease, and ... Full text Link to item Cite

Associations of socioeconomic status and processed food intake with serum phosphorus concentration in community-living adults: the Multi-Ethnic Study of Atherosclerosis (MESA).

Journal Article J Ren Nutr · September 2012 OBJECTIVE: Higher serum phosphorus concentrations are associated with cardiovascular disease events and mortality. Low socioeconomic status is linked with higher serum phosphorus concentration, but the reasons are unclear. Poor individuals disproportionate ... Full text Link to item Cite

FGF-23 levels in patients with AKI and risk of adverse outcomes.

Journal Article Clin J Am Soc Nephrol · August 2012 BACKGROUND AND OBJECTIVES: Fibroblast growth factor 23 plays an important role in regulating phosphate and vitamin D homeostasis. Elevated levels of fibroblast growth factor 23 are independently associated with mortality in patients with CKD and ESRD. Whet ... Full text Link to item Cite

Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease.

Journal Article Int Urol Nephrol · August 2012 BACKGROUND: Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD). Recent data implicate disordered bone and mineral metabolism, including changes in serum levels of calcium, phosphate, parathyroid hormone (PTH) ... Full text Link to item Cite

Effects of phosphate binders in moderate CKD.

Journal Article J Am Soc Nephrol · August 2012 Some propose using phosphate binders in the CKD population given the association between higher levels of phosphorus and mortality, but their safety and efficacy in this population are not well understood. Here, we aimed to determine the effects of phospha ... Full text Link to item Cite

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.

Journal Article Nephrol Dial Transplant · August 2012 BACKGROUND: Optimal treatment for secondary hyperparathyroidism (SHPT) has not been defined. The IMPACT SHPT (ClinicalTrials.gov identifier: NCT00977080) study assessed whether dose-titrated paricalcitol plus supplemental cinacalcet only for hypercalcaemia ... Full text Link to item Cite

Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study.

Journal Article J Ren Nutr · July 2012 BACKGROUND: Protein from plant, as opposed to animal, sources may be preferred in chronic kidney disease (CKD) because of the lower bioavailability of phosphate and lower nonvolatile acid load. STUDY DESIGN: Observational cross-sectional study. SETTING AND ... Full text Link to item Cite

Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients.

Journal Article Diabetes Res Clin Pract · July 2012 UNLABELLED: Our aim was to investigate u-NGAL, u-KIM1 and p-FGF23 and prediction of decline in kidney function in type 2 diabetic patients with proteinuria. METHODS: We performed a follow-up study, follow-up median (range) 3.5 (1-5) years. At baseline u-NG ... Full text Link to item Cite

Fibroblast growth factor 23 and Inflammation in CKD.

Journal Article Clin J Am Soc Nephrol · July 2012 BACKGROUND AND OBJECTIVES: Levels of fibroblast growth factor 23 (FGF23) and inflammatory markers are commonly elevated in CKD, and each is associated with adverse clinical outcomes. This study tested the hypothesis that FGF23 is independently associated w ... Full text Link to item Cite

Mineral metabolism: confusion to clarity.

Journal Article Curr Opin Nephrol Hypertens · July 2012 Full text Link to item Cite

Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease.

Journal Article Diabetes Care · May 2012 OBJECTIVE: Disordered mineral metabolism is a common complication of chronic kidney disease (CKD) and a novel risk factor for CKD progression, cardiovascular disease, and mortality. Although diabetes is the leading cause of CKD and is associated with worse ... Full text Open Access Link to item Cite

Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol.

Journal Article Clin J Am Soc Nephrol · May 2012 BACKGROUND AND OBJECTIVES: Primary prevention of disordered mineral metabolism in CKD necessitates knowledge of its early pathophysiology. This study evaluated daily fluctuations in mineral metabolites in patients with CKD stages 3 and 4 before and after s ... Full text Link to item Cite

Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin.

Journal Article Am J Transplant · February 2012 Inhibitors of the mammalian target of rapamycin (mTOR), sirolimus and everolimus, reduce the incidence of acute rejection following kidney transplantation, but their impact on clinical outcomes beyond 2 years after transplantation is unknown. We examined r ... Full text Link to item Cite

(1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers.

Journal Article Clin J Am Soc Nephrol · January 2012 BACKGROUND AND OBJECTIVES: Fibroblast growth factor 23 (FGF23) regulates phosphorus and vitamin D metabolism. Parathyroid hormone (PTH) infusion for 24 hours stimulated FGF23 secretion in healthy volunteers. The extent to which this was due to a direct sti ... Full text Link to item Cite

FGF23 in chronic kidney disease.

Journal Article Adv Exp Med Biol · 2012 Chronic kidney disease (CKD) is a growing public health epidemic that is associated with a markedly increased risk of cardiovascular mortality. Disordered mineral metabolism and particularly, disordered phosphorus metabolism appears to be a contributing fa ... Full text Link to item Cite

Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study.

Journal Article Clin J Am Soc Nephrol · December 2011 BACKGROUND AND OBJECTIVES: Fibroblast growth factor 23 (FGF23) regulates phosphorus and vitamin D metabolism. Elevated FGF23 concentrations are associated with cardiovascular disease events and mortality across a broad range of kidney function, but the pre ... Full text Link to item Cite

Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease.

Journal Article Clin J Am Soc Nephrol · November 2011 BACKGROUND AND OBJECTIVES: Osteoprotegerin (OPG), a cytokine that regulates bone resorption, has been implicated in the process of vascular calcification and stiffness. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum OPG was measured in 351 participan ... Full text Link to item Cite

FGF23 induces left ventricular hypertrophy.

Journal Article J Clin Invest · November 2011 Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascular disease in individuals with CKD. Elevated levels of FGF23 ha ... Full text Link to item Cite

Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.

Journal Article Clin J Am Soc Nephrol · November 2011 BACKGROUND AND OBJECTIVES: Fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality in patients with ESRD. Before FGF23 testing can be integrated into clinical practice of ESRD, further understanding of its determinants is needed. DE ... Full text Link to item Cite

Hepcidin and disordered mineral metabolism in chronic kidney disease.

Journal Article Clin Nephrol · August 2011 BACKGROUND: Hepcidin regulates iron homeostasis by blocking iron absorption from the gut and iron release from macrophage and hepatocyte stores. Hepcidin levels are elevated in kidney failure and thus, are thought to contribute to dysregulation of iron hom ... Full text Link to item Cite

Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions.

Journal Article J Ren Nutr · July 2011 OBJECTIVE: Vitamin D may promote cardiovascular health in general population and in chronic kidney disease (CKD) through inhibition of the renin-angiotensin system and anti-inflammatory effects. Although proteinuria is a marker of kidney and cardiovascular ... Full text Link to item Cite

The beehive and the merry-go-round in mineral metabolism.

Journal Article Curr Opin Nephrol Hypertens · July 2011 Full text Link to item Cite

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Journal Article JAMA · June 15, 2011 CONTEXT: A high level of the phosphate-regulating hormone fibroblast growth factor 23 (FGF-23) is associated with mortality in patients with end-stage renal disease, but little is known about its relationship with adverse outcomes in the much larger popula ... Full text Link to item Cite

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Journal Article Kidney Int · June 2011 Fibroblast growth factor 23 (FGF23) regulates phosphorus metabolism and is a strong predictor of mortality in dialysis patients. FGF23 is thought to be an early biomarker of disordered phosphorus metabolism in the initial stages of chronic kidney disease ( ... Full text Link to item Cite

Differential effects of vitamin d receptor agonists on gene expression in neonatal rat cardiomyocytes.

Journal Article Cardiovasc Drugs Ther · June 2011 PURPOSE: Vitamin D receptor (VDR) activation is associated with cardiovascular benefits in chronic kidney disease patients, but whether VDR's hormone and prehormone exhibit similar effects requires more studies. METHODS: Neonatal rat cardiomyocytes were tr ... Full text Link to item Cite

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.

Journal Article J Am Soc Nephrol · May 2011 An increased circulating level of fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality, cardiovascular disease, and progression of chronic kidney disease (CKD), but its role in transplant allograft and patient survival is unknown ... Full text Link to item Cite

Reply

Journal Article Nephrology Dialysis Transplantation · May 1, 2011 Full text Cite

Association of serum phosphorus level with anemia in kidney transplant recipients.

Journal Article Transplantation · April 27, 2011 BACKGROUND: Anemia and mineral and bone disorders (MBD) are both important and common complications in kidney transplant recipients. Studies in patients with chronic kidney disease indicated a possible independent association of higher serum phosphorus wit ... Full text Link to item Cite

Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort.

Journal Article Nephrol Dial Transplant · April 2011 BACKGROUND: Secondary hyperparathyroidism is a common complication of chronic kidney disease (CKD) that is associated with bone disease, cardiovascular disease and death. Pathophysiological factors that maintain secondary hyperparathyroidism in advanced CK ... Full text Link to item Cite

Impact of poverty on serum phosphate concentrations in the Third National Health and Nutrition Examination Survey.

Journal Article J Ren Nutr · March 2011 OBJECTIVE: Increased serum phosphate is associated with adverse health outcomes. High intake of inexpensive processed and fast foods is common in impoverished communities, and is linked with excessive dietary phosphorus intake and elevated serum phosphate ... Full text Link to item Cite

Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.

Journal Article Pediatr Transplant · February 2011 Hypophosphatemia caused by inappropriate urinary phosphate wasting is a frequent metabolic complication of the early period following kidney transplantation. Although previously considered to be caused by tertiary hyperparathyroidism, recent evidence sugge ... Full text Link to item Cite

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.

Journal Article Nephrol Dial Transplant · February 2011 BACKGROUND: High levels of fibroblast growth factor 23 (FGF23) are associated with mortality and progression of chronic kidney disease (CKD). Reducing dietary phosphorus intake lowers FGF23 secretion in healthly individuals, but there is little data on its ... Full text Link to item Cite

Racial differences in postprandial mineral ion handling in health and in chronic kidney disease.

Journal Article Nephrol Dial Transplant · December 2010 BACKGROUND: Increased serum phosphate is associated with cardiovascular disease. Compared with whites, blacks have significantly higher serum phosphate and increased risk of hyperphosphataemia in health and chronic kidney disease (CKD). While population-ba ... Full text Link to item Cite

Low socioeconomic status associates with higher serum phosphate irrespective of race.

Journal Article J Am Soc Nephrol · November 2010 Hyperphosphatemia, which associates with adverse outcomes in CKD, is more common among blacks than whites for unclear reasons. Low socioeconomic status may explain this association because poverty both disproportionately affects racial and ethnic minoritie ... Full text Link to item Cite

FGF23 or PTH: which comes first in CKD ?

Journal Article Kidney Int · November 2010 In the past 40 years, disordered mineral metabolism has been among the most intensely studied areas of nephrology. A June 2010 PubMed search for 'secondary hyperparathyroidism and kidney disease' yielded 5866 references. Among these are papers documenting ... Full text Link to item Cite

FGF23: fashion or physiology?

Journal Article Clin J Am Soc Nephrol · October 2010 Full text Link to item Cite

FGF-23: More than a regulator of renal phosphate handling?

Journal Article J Bone Miner Res · October 2010 Fibroblast growth factor 23 (FGF-23) is likely to be the most important regulator of phosphate homeostasis, which mediates its functions through FGF receptors and the coreceptor Klotho. Besides reducing expression of the sodium-phosphate cotransporters NPT ... Full text Link to item Cite

Forging forward with 10 burning questions on FGF23 in kidney disease.

Journal Article J Am Soc Nephrol · September 2010 The discovery of fibroblast growth factor 23 (FGF23) as the causal factor in the pathogenesis of rare forms of hypophosphatemic rickets is rapidly reshaping our understanding of disordered mineral metabolism in chronic kidney disease (CKD). Excessive produ ... Full text Link to item Cite

Chronic kidney disease in patients with cognitive impairment: A marker of microvascular damage or an independent risk factor?

Journal Article Aging Health · August 1, 2010 Evaluation of: Yaffe K, Ackerson L, Tamura MK et al.: Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J. Am. Geriatr. Soc. 58, 338-345 (2010). The effect of chronic kidney ... Full text Cite

Common genetic determinants of vitamin D insufficiency: a genome-wide association study.

Journal Article Lancet · July 17, 2010 BACKGROUND: Vitamin D is crucial for maintenance of musculoskeletal health, and might also have a role in extraskeletal tissues. Determinants of circulating 25-hydroxyvitamin D concentrations include sun exposure and diet, but high heritability suggests th ... Full text Link to item Cite

Diagnosis and management of mineral metabolism in CKD.

Journal Article J Gen Intern Med · July 2010 BACKGROUND: Chronic kidney disease (CKD) affects over 26 million Americans and is frequently complicated early in its course by disordered mineral metabolism and metabolic bone disease. Since CKD-related bone loss is often indistinguishable from osteoporos ... Full text Link to item Cite

Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease.

Journal Article Curr Opin Nephrol Hypertens · July 2010 PURPOSE OF REVIEW: In recent years, there has been an increasing awareness of the central regulatory role of fibroblast growth factor 23 (FGF23) in mineral metabolism and its particular prominence in patients with chronic kidney disease (CKD). RECENT FINDI ... Full text Link to item Cite

Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.

Journal Article Nephrol Dial Transplant · July 2010 BACKGROUND: Patients with iron deficiency anaemia (IDA) in the setting of non-dialysis-dependent chronic kidney disease (NDD-CKD) may benefit from treatment with intravenous (IV) iron. Ferric carboxymaltose (FCM) is a novel IV iron formulation designed to ... Full text Link to item Cite

Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury.

Journal Article Nephrol Dial Transplant · April 2010 Rhabdomyolysis-induced acute kidney injury (AKI) is characterized by hyperphosphataemia and hypocalcaemia. Despite appropriate secondary elevation of parathyroid hormone (PTH) in response to hypocalcaemia, rhabdomyolysis and AKI are associated with acute d ... Full text Link to item Cite

Vitamin D deficiency and anemia in early chronic kidney disease.

Journal Article Kidney Int · April 2010 Vitamin D has a number of pleiotropic effects in a variety of tissues, in addition to its well-known effects on mineral metabolism. To determine whether it has an effect on erythropoiesis, we studied the association of the components of the vitamin D axis ... Full text Link to item Cite

Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active

Journal Article Journal of Clinical Endocrinology and Metabolism · January 1, 2010 Context: Fibroblast growth factor 23 (FGF23) regulates phosphorus homeostasis and vitamin D metabolism. Circulating FGF23 levels are elevated in inherited and acquired hypophosphatemic disorders that can cause rickets or osteomalacia. Particularly increase ... Full text Cite

Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies.

Journal Article Semin Dial · 2010 Hyperphosphatemia is an independent risk factor for mortality in patients on maintenance dialysis. Since phosphorus clearance by standard three times-weekly dialysis is insufficient to balance ongoing dietary phosphorus intake, strategies to prevent absorp ... Full text Link to item Cite

Response to Targeting hyperphosphatemia: Truth or dare

Journal Article Kidney International · January 1, 2010 Full text Cite

The authors reply

Journal Article Kidney International · January 1, 2010 Full text Cite

Second chances in mineral metabolism.

Journal Article Clin J Am Soc Nephrol · January 2010 Full text Link to item Cite

The authors reply

Journal Article Kidney International · January 1, 2010 Full text Cite

Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study.

Journal Article Diabetes · January 2010 OBJECTIVE: Because vitamin D deficiency is associated with a variety of chronic diseases, understanding the characteristics that promote vitamin D deficiency in otherwise healthy adults could have important clinical implications. Few studies relating vitam ... Full text Link to item Cite

Fibroblast growth factor 23 and the future of phosphorus management.

Journal Article Curr Opin Nephrol Hypertens · November 2009 PURPOSE OF REVIEW: To present emerging data on the role of fibroblast growth factor 23 (FGF23) in mineral metabolism and adverse outcomes in chronic kidney disease (CKD). RECENT FINDINGS: FGF23 regulates phosphorus and vitamin D metabolism. Its levels incr ... Full text Link to item Cite

Klotho variants and chronic hemodialysis mortality.

Journal Article J Bone Miner Res · November 2009 Patients with end-stage renal disease (ESRD) suffer exceptionally high mortality rates in their first year of chronic hemodialysis. Both vitamin D and fibroblast growth factor (FGF)-23 levels correlate with survival in these patients. Klotho is a protein i ... Full text Link to item Cite

Chronic kidney disease, hypovitaminosis D, and mortality in the United States.

Journal Article Kidney Int · November 2009 Low serum 25-hydroxy vitamin D (25OHD) predicts a higher cardiovascular risk in the general population. Because patients with chronic kidney disease are more likely to have low serum 25OHD, we determined the relationship between hypovitaminosis D and death ... Full text Link to item Cite

A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease.

Journal Article Kidney Int · October 2009 The diagnosis of chronic kidney disease (CKD) confers dismal clinical outcomes regardless of whether patients are initiating dialysis and face a median survival of only 2-3 years or they have earlier-stage CKD and face a risk of death that is greater than ... Full text Link to item Cite

Integrating research training into residency: tools of human investigation.

Journal Article Acad Med · September 2009 Although the need for new physician-clinical scientists has never been greater, significant obstacles deter young physicians from careers in clinical research. Local and federal programs have sought to stimulate interest in clinical research among young ph ... Full text Link to item Cite

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Journal Article Circulation · May 19, 2009 BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone. In chronic kidney disease (CKD), circulating FGF-23 levels are markedly elevated and independently associated with mortality. Left ventricular hypertrophy and coronary art ... Full text Link to item Cite

Plasma gelsolin and circulating actin correlate with hemodialysis mortality.

Journal Article J Am Soc Nephrol · May 2009 Plasma gelsolin (pGSN) binds actin and bioactive mediators to localize inflammation. Low pGSN correlates with adverse outcomes in acute injury, whereas administration of recombinant pGSN reduces mortality in experimental sepsis. We found that mean pGSN lev ... Full text Link to item Cite

Phosphorus binders and survival on hemodialysis.

Journal Article J Am Soc Nephrol · February 2009 Although hyperphosphatemia is a risk factor for mortality, there are limited data on whether therapy with phosphorus binders affects survival. We analyzed a prospective cohort study of 10,044 incident hemodialysis patients using Cox proportional hazards an ... Full text Link to item Cite

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

Journal Article N Engl J Med · August 7, 2008 BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a hormone that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperphosphatemia in patients with kidney disease. Hy ... Full text Link to item Cite

N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements.

Journal Article Clin Chem · August 2008 BACKGROUND: Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associated with increased cardiovascular mortality in chronic hemodialysis patients. Previous studies focused on prevalent dialysis patients and examined single ... Full text Link to item Cite

Active vitamin D and survival.

Journal Article J Am Soc Nephrol · August 2008 Full text Link to item Cite

Impact of activated vitamin D and race on survival among hemodialysis patients.

Journal Article J Am Soc Nephrol · July 2008 Contrary to most examples of disparities in health outcomes, black patients have improved survival compared with white patients after initiating hemodialysis. Understanding potential explanations for this observation may have important clinical implication ... Full text Link to item Cite

Calciphylaxis from nonuremic causes: a systematic review.

Journal Article Clin J Am Soc Nephrol · July 2008 BACKGROUND AND OBJECTIVES: Calciphylaxis, or calcific uremic arteriolopathy, is a well-described entity in end-stage kidney disease and renal transplant patients; however, little systematic information is available on calciphylaxis from nonuremic causes. T ... Full text Link to item Cite

Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease.

Journal Article Kidney Int · April 2008 Disorders of mineral metabolism develop early in chronic kidney disease, but it appears that Blacks with stage-5 disease have more severe secondary hyperparathyroidism than other races. We measured levels of parathyroid hormone, calcium, phosphorus, 25-hyd ... Full text Link to item Cite

Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.

Journal Article J Am Soc Nephrol · March 2008 Normophosphatemia and normocalcemia are maintained in chronic kidney disease (CKD) by increased levels of fibroblast growth factor-23 (FGF-23) and parathyroid hormone (PTH), but the stimuli for secretion of these hormones in early CKD are incompletely unde ... Full text Link to item Cite

Renal metastases.

Journal Article Kidney Int · February 2008 Full text Link to item Cite

Vitamin D deficiency and risk of cardiovascular disease.

Journal Article Circulation · January 29, 2008 BACKGROUND: Vitamin D receptors have a broad tissue distribution that includes vascular smooth muscle, endothelium, and cardiomyocytes. A growing body of evidence suggests that vitamin D deficiency may adversely affect the cardiovascular system, but data f ... Full text Link to item Cite

Improving survival of dialysis patients with active vitamin D

Journal Article Nieren- und Hochdruckkrankheiten · January 1, 2008 Cardiovascular disease is the leading cause of death among patients on hemodialysis. Secondary hyperparathyroidism (sHPT), hyperphosphatemia, hypocalcemia and deficiency of calcitriol, the active hormonal form of vitamin, are common complications of chroni ... Full text Cite

Vitamin D levels and early mortality among incident hemodialysis patients.

Journal Article Kidney Int · October 2007 Vitamin D deficiency is associated with cardiovascular disease, the most common cause of mortality in hemodialysis patients. To investigate the relation between blood levels of 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D) with hemodialysis ... Full text Link to item Cite

First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction.

Journal Article Am J Obstet Gynecol · July 2007 OBJECTIVE: The purpose of this study was to evaluate first-trimester serum placental protein 13 (PP13) as a screening test for preeclampsia and intrauterine growth restriction (IUGR). STUDY DESIGN: We performed a prospective, nested case-control study in t ... Full text Link to item Cite

Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey.

Journal Article Arch Intern Med · June 11, 2007 BACKGROUND: Results of several epidemiologic and clinical studies have suggested that there is an excess risk of hypertension and diabetes mellitus in persons with suboptimal intake of vitamin D. METHODS: We examined the association between serum levels of ... Full text Link to item Cite

Predicting gestational diabetes: choosing the optimal early serum marker.

Journal Article Am J Obstet Gynecol · April 2007 OBJECTIVE: Serum markers measured early in pregnancy have been associated with the later diagnosis of gestational diabetes mellitus. To select an optimal early (<20 weeks) marker, we prospectively compared 3 serum markers examined simultaneously in a singl ... Full text Link to item Cite

Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward.

Journal Article J Steroid Biochem Mol Biol · March 2007 Although approximately half of patients undergoing hemodialysis receive activated forms of Vitamin D, the primary reason to initiate this therapy has rested solely on the management of secondary hyperparathyroidism. Secondary hyperparathyroidism is likely ... Full text Link to item Cite

Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia.

Conference Hypertension · March 2007 Activating angiotensin II type 1 autoantibodies (AT1-AAs) develop in women with preeclampsia and may contribute to the disorder. Insulin resistance and serum concentrations of the antiangiogenic soluble fms-like tyrosine kinase 1 (sFlt-1) are also increase ... Full text Link to item Cite

Vitamin D in patients with kidney disease: cautiously optimistic.

Journal Article Adv Chronic Kidney Dis · January 2007 Nephrologists are well aware of the therapeutic effects of activated vitamin D in managing secondary hyperparathyroidism. Beyond bone and mineral metabolism, however, we are now beginning to appreciate the effects of activating the vitamin D receptor (VDR) ... Full text Link to item Cite

Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?

Journal Article Kidney Int · October 2006 Hypophosphatemia is a common complication of kidney transplantation. Tertiary hyperparathyroidism has long been thought to be the etiology, but hypophosphatemia can occur despite low parathyroid hormone (PTH) levels and can persist after high PTH levels no ... Full text Link to item Cite

Clinical problem-solving. Needle in a haystack.

Journal Article N Engl J Med · January 5, 2006 Full text Link to item Cite

Postpartum diabetes screening in women with a history of gestational diabetes.

Journal Article Obstet Gynecol · December 2005 OBJECTIVE: Women with a history of gestational diabetes mellitus (GDM) are at high risk for developing type 2 diabetes (diabetes mellitus, DM). The American Diabetes Association recommends regular postpartum diabetes screening for women with a history of G ... Full text Link to item Cite

Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women.

Journal Article Placenta · August 2005 The soluble VEGF receptor, sFlt-1 (otherwise referred to as sVEGFR-1), has been implicated in the pathogenesis of preeclampsia. The preeclamptic placenta has been previously demonstrated to produce high levels of the soluble VEGF receptor. Here we tested t ... Full text Link to item Cite

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Journal Article J Am Soc Nephrol · July 2005 Hyperphosphatemia, calcitriol deficiency, and secondary hyperparathyroidism (SHPT) are common complications of chronic kidney disease (CKD). Fibroblast growth factor-23 (FGF-23) is a novel phosphaturic hormone that also inhibits renal 1alpha-hydroxylase ac ... Full text Link to item Cite

Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies.

Journal Article Am J Obstet Gynecol · July 2005 Preeclampsia is far more common in women's first pregnancy but the mechanism of this association is unknown. Altered angiogenesis, marked by increased levels of circulating soluble fms-like tyrosine kinase (sFlt-1), an inhibitor of placental growth factor ... Full text Link to item Cite

Activated injectable vitamin D and hemodialysis survival: a historical cohort study.

Journal Article J Am Soc Nephrol · April 2005 Patients with ESRD commonly experience secondary hyperparathyroidism, a condition primarily managed with activated injectable vitamin D. The biologic effects of vitamin D, however, are widespread, and it is possible that activated injectable vitamin D alte ... Full text Link to item Cite

Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.

Journal Article Semin Dial · 2005 Secondary hyperparathyroidism is a common complication of end-stage renal disease (ESRD) that is often treated with activated forms of intravenous vitamin D. The natural course and treatment of secondary hyperparathyroidism in hemodialysis patients is punc ... Full text Link to item Cite

Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance.

Journal Article J Clin Endocrinol Metab · December 2004 Altered angiogenesis and insulin resistance are associated with preeclampsia and cardiovascular disease (CVD), and women with preeclampsia appear to be at increased risk of future CVD. We hypothesized that these factors are detectable in asymptomatic postp ... Full text Link to item Cite

Differential risk of hypertensive disorders of pregnancy among Hispanic women.

Journal Article J Am Soc Nephrol · May 2004 Preeclampsia and gestational hypertension are leading complications of pregnancy that also portend increased risk of future chronic hypertension. Although rates of chronic hypertension differ between non-Hispanic Caucasian and Hispanic women, few studies e ... Full text Link to item Cite

Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia.

Journal Article Hypertension · May 2004 Altered angiogenesis and insulin resistance, which are intimately related at a molecular level, characterize preeclampsia. To test if an epidemiological interaction exists between these two alterations, we performed a nested case-control study of 28 women ... Full text Link to item Cite

First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.

Journal Article J Clin Endocrinol Metab · February 2004 An imbalance of pro- and antiangiogenic factors may lead to preeclampsia (PE). In this prospective nested case-control study, we investigated whether first trimester serum levels of placental growth factor (PlGF), a potent angiogenic factor, and its solubl ... Full text Link to item Cite

Inflammation and glucose intolerance: a prospective study of gestational diabetes mellitus.

Journal Article Diabetes Care · January 2004 OBJECTIVE: Increased leukocyte count is a marker of inflammation that has been associated with the development of type 2 diabetes in prospective studies. Although gestational diabetes mellitus (GDM) and type 2 diabetes share certain pathophysiological mech ... Full text Link to item Cite

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

Journal Article N Engl J Med · July 31, 2003 BACKGROUND: Elevated calcium and phosphorus levels after therapy with injectable vitamin D for secondary hyperparathyroidism may accelerate vascular disease and hasten death in patients undergoing long-term hemodialysis. Paricalcitol, a new vitamin D analo ... Full text Link to item Cite

First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus.

Journal Article Am J Obstet Gynecol · July 2003 OBJECTIVE: We sought to examine the association between early pregnancy levels of sex hormone binding globulin and subsequent gestational diabetes mellitus, an association that has not been studied previously. STUDY DESIGN: We conducted a nested case-contr ... Full text Link to item Cite

First-trimester C-reactive protein and subsequent gestational diabetes.

Journal Article Diabetes Care · March 2003 OBJECTIVE: Systemic inflammation is associated with the development of type 2 diabetes. We tested the hypothesis that increased inflammation, measured early in pregnancy, is associated with the subsequent development of gestational diabetes mellitus (GDM), ... Full text Link to item Cite

Insulin resistance but not inflammation is associated with gestational hypertension.

Journal Article Hypertension · December 2002 Hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia, are leading causes of pregnancy-associated morbidity. Although insulin resistance and inflammation contribute to preeclampsia, prospective data regarding mechanisms o ... Full text Link to item Cite

Clinical research career development: the individual perspective.

Journal Article Acad Med · November 2002 The process of integrating medical scientific breakthroughs into improved clinical practice requires talented and dedicated clinical investigators. Unfortunately, substantial impediments deter gifted physicians from clinical research. The experience of "Dr ... Full text Link to item Cite

First trimester insulin resistance and subsequent preeclampsia: a prospective study.

Journal Article J Clin Endocrinol Metab · April 2002 Insulin resistance is implicated in the pathogenesis of preeclampsia, but prospective data are limited. SHBG, a marker of insulin resistance among nonpregnant individuals, has not been studied in detail during pregnancy. We conducted a prospective, nested, ... Full text Link to item Cite

Patients with Fabry disease on dialysis in the United States.

Journal Article Kidney Int · January 2002 BACKGROUND: : Fabry disease results from an X-linked deficiency of lysosomal alpha-galactosidase A and is a rare cause of end-stage renal disease. Little is known about the characteristics of patients with Fabry disease that initiate dialysis in the United ... Full text Link to item Cite

Obesity and preeclampsia: the potential role of inflammation.

Journal Article Obstet Gynecol · November 2001 OBJECTIVE: Systemic inflammation might contribute to the pathogenesis of preeclampsia. In addition, the association between obesity and inflammation in preeclampsia has not been examined in detail. We determined whether first-trimester elevation of serum C ... Full text Link to item Cite

Case of the month misdiagnosis.

Journal Article Am J Med · February 15, 2000 Full text Link to item Cite